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O cancro da mama é a forma mais frequente de cancro nas mulheres, a nível mundial. A taxa 
de mortalidade que se lhe associa tem-se mantido mais ou menos constante, isto apesar dos 
avanços tecnológicos observados recentemente relativamente ao diagnóstico precoce e à 
terapêutica. Uma das causas deste cenário é a inexistência de biomarcadores séricos 
validados que permitam a implementação de diagnóstico precoce.  
Neste contexto, os miRNAs têm vindo a despertar um especial interesse na comunidade 
científica, enquanto biomarcadores promissores e emergentes no diagnóstico precoce do 
cancro. No cancro da mama, os níveis de expressão de diversos miRNAs são 
significativamente diferentes entre os tecidos normais e os tecidos com a neoplasia, bem 
como entre subtipos moleculares do cancro da mama diferentes, associados também a 
prognóstico.  
Neste sentido, este trabalho descreve uma revisão sistemática para a identificação do miRNA 
a ser estudado. Após meta-análise, selecionou-se o miRNA-155 para o desenvolvimento de 
um biossensor eletroquímico dedicado à deteção deste miRNA em amostras de soro. O 
biossensor foi construído em três estágios diferentes: (1) imobilização do oligonucleótido 
complementar tioloado (anti-miRNA-155) na superfície de um elétrodo de ouro impresso 
(Au-SPE), seguindo-se (2) o bloqueio de ligações não-específicas com ácido 
mercaptossuccínico e finalizando com a (3) hibridação do respetivo miRNA. 
O biossensor detetou concentrações de miRNA da ordem dos 10-18 mol/L (aM), 
apresentando uma resposta linear entre 10 aM e 1 nM. O biossensor apresentou ainda um 
baixo limite de deteção em amostras reais de soro humano, igual a 5.7 aM, e uma boa 
seletividade quando na presença de outras biomoléculas de grande dimensão, como o 
antigénio do cancro da mama CA-15.3 e a albumina de soro bovino (BSA).  
Esta abordagem simples e sensível demonstrou ser uma estratégia promissora para a análise 
quantitativa e/ou simultânea de múltiplos miRNA em fluidos fisiológicos, no que concerne 
à extensão da investigação biomédica na área da monitorização de biomarcadores e ao 
diagnóstico em ponto de cuidado. 
 
Palavras-Chave: Cancro da mama; miRNA; miRNA-155; biossensores eletroquímicos; 
meta-análise.
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Breast cancer is one of the most prevalent forms of cancer in women. Despite all recent 
advances in early diagnosis and therapy, mortality data is not decreasing. This is an outcome 
of the inexistence of validated serum biomarkers allowing an early prognosis, out coming 
from the limited understanding of the natural history of the disease.  
In this context, miRNAs have been attracting a special interest throughout the scientific 
community as promising biomarkers in the early diagnosis of cancer. In breast cancer, 
several miRNAs and their levels of expression are significantly different between normal 
tissue and tissue with neoplasia, as well as between different molecular subtypes of breast 
cancer, also associated with prognosis.  
Thus, this these presents a meta-analysis that allows identifying a reliable miRNA biomarker 
for the early detection of breast cancer. In this, miRNA-155 was identified as the best one 
and an electrochemical biosensor was developed for its detection in serum samples. The 
biosensor was assembled by following three button-up stages: (1) the complementary 
miRNA sequence thiol terminated (anti-miRNA-155) was immobilized on a commercial 
gold screen-printed electrode (Au-SPE), followed by (2) blocking non-specific binding with 
mercaptosuccinic acid and by (3) miRNA hybridization.  
The biosensor was able to detect miRNA concentrations lying in the 10-18 mol/L (aM) range, 
displaying a linear response from 10 aM to 1nM. The device showed a limit of detection of 
5.7 aM in human serum samples and good selectivity against other biomolecules in serum, 
such as cancer antigen CA-15.3 and bovine serum albumin (BSA).  
Overall, this simple and sensitive strategy is a promising approach for the quantitative and/or 
simultaneous analysis of multiple miRNA in physiological fluids, aiming at further 
biomedical research devoted to biomarker monitoring and point-of-care diagnosis. 
 
Keywords: Breast cancer; miRNA; miRNA-155; electrochemical biosensors; meta-
analysis. 
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I. CHAPTER  
I.1.  Introduction  
I.1.1. Framework 
This thesis is organized in five chapters. Chapter I presents a brief state-of-art of current 
methods and technologies applied to the assessment of miRNAs as cancer biomarkers. A 
description of recognition elements used for the new design of biosensors is presented 
next. Several electrochemical and optical systems are also reviewed, emphasizing 
characteristics that biosensors should exhibit for a successful practical application.  
Chapter II describes de main aspects of experimental nature, from the selection of 
miRNA to the development of the biosensor involved in miRNA-155 detection.  
Chapter III presents the main results of the present research work. It includes the 
description of the systematic review of miRNA in breast cancer (chapter III-2). This part 
of the study was performed according to systematic reviews guidelines in order to 
establish the overall diagnostic accuracy of the measurement of microRNA in the 
diagnosis of breast cancer. The systematic review was performed with 14 studies, 
involving 1897 patients available for analysis. This systematic review addressed the three 
types of the most described microRNAs in breast cancer (miRNA-155, miRNA-145, 
miRNA-181a).  
The development of a rapid and sensitive electrochemical biosensor for detection of 
miRNA-155 was also described in this chapter (chapter III-3). For this purpose, the 
capture probe was immobilized on a gold screen printed electrode (Au-SPE) surface and 
each step of the modification process was characterized by electrochemical and AFM 
techniques. The analytical features of the resulting biosensor were studied by different 
electrochemical techniques. The biosensor was successfully applied to biological fluids 
showing ultrasensitive limits.  
The Chapter IV summarizes the main conclusions obtained and presents guidelines for 
future research work   
Chapter V lists the references cited herein.  
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I.1.3. Brief of State-of-art  
I.1.3.1. Cancer biomarkers 
Breast cancer is considered the leading cause of death of women in the world. Actually, 
several diagnostic and therapeutic innovations have been reported, but their effect on 
mortality is still discrete. It can be due the little understanding about the natural history 
of the disease, concerning mainly the progression from in situ to invasive breast 
carcinoma, which is a life-threatening condition. In addition, there are no validated serum 
biomarkers for early prognosis that are sensitive and specific enough to be used routinely.  
In this context, miRNA have been gaining interest within the scientific community as 
biomarker of early prognosis in cancer disease (Perry et al., 2008). The miRNAs are non-
coding RNA species, containing 18-24 nucleotides. They regulate gene expression post-
transcriptionally via specific interaction with the 3 'UTR sequence of the target mRNA, 
resulting in the translation inhibition and/or mRNA degradation. They also play an 
essential role in biological processes such as development, cell proliferation, apoptosis, 
stress response, and tumorigenesis (Fu, Chen, & Man, 2011). 
Their discovery and functional understanding have only been disclosed in the past ten 
years. Long large primary transcripts (pre-miRNAs) are transcribed from the genome and 
processed into pre-miRNAs by Dicer; and then into short single stranded mature miRNAs 
complexed with Argonaute proteins to inhibit protein translation. The first link of 
miRNAs to cancer was made only recently, in 2007, but the field has expanded 
exponentially since (Campuzano, Pedrero, & Pingarrón, 2014). 
The expression levels of various miRNAs in breast cancer differ significantly from 
healthy states. Differences are observed between normal and neoplasic tissues, and within 
different molecular subtypes of breast cancer diseases that show unrelated prognosis and 
different responses to therapy. In addition, aberrant expression miRNAs have been 
observed in several breast cancer solid tumours (Riaz et al., 2013). 
I.1.3.2. miRNA-155 as cancer biomarker 
In order to understand which miRNA could exhibit suitable biomarker properties in breast 
cancer, a systematic review of miRNA was described (Chapter III-2) in this thesis. This 
review allowed confirming that miRNA-155 showed relevant scientific evidence as 
biomarker in breast cancer. 
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The miRNA-155 has been previously shown up-regulated in breast cancer, thus being 
considered as an oncoMIR. Deregulation of its expression is involved in numerous 
pathological processes and oncogenic signalling. In addition, miRNA-155 was 
significantly increased in sera from breast cancer patients compared with normal controls 
(Mattiske, Suetani, Neilsen, & Callen, 2012). Furthermore, miRNA-155 expression was 
inversely correlated with estrogen receptor (ER) and progesterone receptor (PR) 
expression, regardless of epidermal growth factor receptor-2 (HER-2) status. These 
findings suggest that miRNA-155 expression is deregulated in breast cancer and is 
involved in the oncogenesis of breast tumours (Zeng, Fang, Nam, Cai, & Long, 2014). 
Besides, the overexpression of miRNA-155 is considered as a breast cancer risk factor 
and some studies showed it can be associated to clinical-pathological markers, tumour 
subtype, poor survival rates, metastasis events and invasive properties of breast cancer, 
as well as high tumour grade, and advanced stage lymph node metastasis (Lautner & 
Gyurcsányi, J. Liu, Huang, Yang, & Luo, 2015).  
The existence of a potential biomarker, or set of miRNA biomarkers, miRNA-155 in this 
case, opens doors towards to a simple serological test for the prognosis/diagnosis of breast 
cancer or monitoring the disease progression against therapy in point-of-care (POC). This 
creates the clinical need for a device capable of performing this analysis on-site (Zeng et 
al., 2014).  
Thus, a suitable method for miRNA-155 detection in biological fluids is strongly and 
urgently required. Amongst the wide range of standard techniques that may be employed 
for the determination of miRNA-155 in serum samples, requirements for sensitivity, 
rapidity, robustness, reliability and low-cost are fundamental, with biosensors meeting 
most of these features. Biosensors are currently an alternative to conventional methods 
like Northern blotting and in situ Hybridization, providing fast results, being portable and 
allowing direct sample reading, thereby avoiding the need to move samples to the 
laboratory (Hamidi-Asl, Hasheminejad, & Mascini, 2013). 
I.1.3.3. Biosensors 
Biosensors are devices converting the interaction of a biorecognition element with a target 
analyte into a measurable signal, mostly of optical or electrical nature. These devices 
combine the specificity of interaction of an analyte of interest with a biological/chemical 
component, called (bio)recognition element, with the sensitivity of a transducer that 
converts such interaction into a measurable signal that is proportional to the analyte 
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concentration (Figure 1). The specificity/sensitivity of a biosensor are therefore 
depending directly of the specificity/sensitivity of the (bio)recognition element for the 
target compound (Grieshaber, MacKenzie, Vörös, & Reimhult, 2008).  
The construction of any biosensor depends primarily of the targeted application. Several 
relevant features are included herein, such as sensitivity requirements, sample 
characteristics (composition, stability, volume available), cost and lifetime. Furthermore, 
the application of a biosensor as an analytical tool in real conditions is restricted to 
specific features, namely, high selectivity, wide range of concentrations, accuracy and 
precision, short response time and recovery, high sampling frequency and operating 
stability, and high reproducibility (Marli & Paiva, 2011).  
 
Figure 1. Overall scheme of biosensor device. 
 
The (bio)recognition element is a crucial part in a biosensor, since it determines the degree 
of selectivity of the device. Typically, biologically-based recognition elements used, such 
as biomolecules, organelles or cells. But synthetic recognition elements, such as 
biomimetic materials that are prepared in the laboratory and designed to mimic a specific 
biological property (Figure 2), may also be employed, offering greater stability and 
reproducibility than their natural counterparts (Bohunicky & Mousa, 2011).  
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The range of analyte concentrations to which the device is sensitive is often associated 
with the selected transduction system. In this context, both electrochemical and optical 
devices are popular, yielding mostly fast measures, of low cost, and automation 
feasibility. Thus, the selection of a suitable combination of recognition element and 
transducer is essential when developing a biosensor (Su, Jia, Hou, & Lei, 2011).  
Figure 2. Biosensing device schematic representation with biorecognition and transduction elements. 
 
I.1.3.3.1. Biorecognition elements 
Each recognition element must contain a binding site for interacting with a target analyte 
present. This interaction should be stable against environment and measurement 
conditions and its mode of actuation varies mostly with the chemical nature of this 
element and its analyte. It can range from affinity processes, such as those related to the 
interaction between an antibody and its antigen, to catalytic reactions, resulting from the 
action of an enzyme on its substrate. Indeed, enzymes and antibodies are the most used 
recognition elements in biosensors (Song, Xu, & Fan, 2006). 
There are several different recognition elements in particular the proteins receptors, 
antibodies, antigens, enzymes, molecularly-imprinted polymers and nucleic acids. When 
the recognition component is an enzyme biosensor, the biosensor is identified as 
enzymatic. These biosensors were the first to show up and have as an advantage the fact 
that enzymes are highly specific/selective biological catalysts. There are however some 
disadvantages associated with these biosensors, in particular the reduced stability of these 
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materials of biological origin, changing its activity by varying pH and temperature (Choi, 
Kwak, & Park, 2010).  
Biosensors utilizing antibodies as recognition elements are known as immunosensors. 
Typically, antibodies are bound to the transducer, and its interaction with the antigen is 
detected by various transducers. The great advantage of using antibodies relates to the 
high affinity and selectivity for these materials present in the target antigen, allowing a 
direct contact of a complex sample with a biosensor recognition surface. However, as 
enzymes, their performance varies with the external conditions of the environment 
(Perumal & Hashim, 2014).  
Thus, recognition elements of synthetic origin that try to mimic the biological properties 
of materials have been assuming a growing role in the field of chemosensors. In essence, 
these materials must show a high affinity and selectivity for the target analyte or catalytic 
ability to transform also in a selective and sensitive way, a compound that is measurable 
by the transducer. A molecular recognition element may be connected to a different 
number of signal transducers (Perumal & Hashim, 2014). The transducer converts the 
electrical signal into a molecular or digital signal that can be measured, displayed, and 
analysed.  
Transducers fall into four general categories, measuring electrochemical (namely 
amperometric and potentiometric), optical (ie, colorimetric, fluorescent, luminescent, and 
interferometry), mass (i.e., piezoelectric and acoustic waves) and calorimetric properties 
(temperature-based). The transducer of any biosensor must be able to adapt the 
recognition element, provide specificity for monitoring the measured property, and 
present high sensitivity for the current change in the concentration range of interest 
(Putzbach & Ronkainen, 2013). 
 
I.1.3.3.2. Electrochemical biosensors 
Electrochemical biosensors are the most common type of biosensors used today due to 
their portability, cost effectiveness, small size, and easy use. Electrochemical biosensors 
can be used at home or in the doctor’s office as POC devices (Johnson & Mutharasan, 
2014). Few electrochemical biosensors for the detection of miRNA have been developed 
so far, relying mostly on miRNAs labelled with electrocatalytic moieties or nanoparticle 
tags. However, such procedures need to enrich and label miRNAs, thereby increasing the 
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complexity of the operation. This has been justified by the low abundance of miRNAs in 
real samples (Labib & Berezovski, 2015). 
The transduction element in electrochemical miRNA biosensors is often based in gold 
(Au) supports. Sensing is accomplished by measuring changes in the electrode or 
interfacial properties upon hybridization between the immobilized complementary DNA 
probe and the miRNA target. Nevertheless, label-free electrochemical biosensors have 
attracted attention in order to increase simplicity. They involve direct or catalysed 
oxidation of RNA bases, as redox reactions of reporter molecules, enzymes, and viral 
proteins recruited to the electrode surface by specific RNA probe-target interactions 
(Jamali, Pourhassan-Moghaddam, Dolatabadi, & Omidi, 2014). 
Transduction in electrochemical miRNA biosensors has been investigated via 
amperometric, potentiometric, resistive and impedance-based approaches. Amperometric 
transducers rely on oxidation/reduction reactions, producing a current, which can then be 
measured. Amperometric-based biosensors for cancer detection that make use of specific 
DNA sequences as recognition element may turn out an extremely useful tool in cancer 
diagnosis. These sensors can detect the presence of gene mutations associated with cancer 
through recognition of and hybridization to specific DNA sequences, present in genomes 
of cancerous cells. Also, electrochemical biosensors offer the capability of detecting 
damaged DNA as well as the carcinogens that caused the damage (Tran et al., 2014). 
Electrochemical transducer technology is also widely used in immunoassays and protein 
arrays. Immunosensors, in which an antibody is coupled to an electrochemical transducer, 
have also been used for measuring cancer biomarkers. Several studies have been made 
combining miRNA and electrochemical biosensors, and these have been summarized in 
table I. Overall, most of the overall designs have been made in a complex way, aiming to 
ensure the good performance of the device.   
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Table I: Electrochemical biosensors for miRNA detection. 
a) Graphene Oxide; b) Gold Nanoparticles; c) Glassy Carbon Electrode; d) Differential Pulse Voltammetry; 
e)Quantum Dots; f) Square Wave Voltammetry; g) Lead Nanoparticles; h) Cyclic Voltammetry; i) Gold 
Nanorods; j) Glassy Carbon Electrode; k) Differential pulse voltammetry; l) Gold Screen Print Electrodes; 
m) Electrochemical Impedance Spectroscopy; 
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Based on the conductive self-assembled multilayer 
comprised of Nafion, thionine (Thi) and Pd 
nanoparticles was successfully prepared. Nafion was 
firstly dropped on to a bare glass carbon electrode. 
Then Thi was absorbed by the cation exchanger 
Nafion.  Pd nanoparticles layer which was used to 
immobilize target biomolecules was constructed by 
the amino group of Thi as linker.  
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Nafion/thionine/H2O.  The method is based on the 
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ligase chain reaction (LCR) and the remarkable 
voltammetric signature of electrochemical QDs 
barcodes. Two reporting probes of RP1 and RP2 were 
labeled with PbS and CdS quantum dots to prepare 
PbS–RP1 and CdS–RP2 conjugates, and two capture 
probes of CP1 and CP2 were co-immobilized on 
magnetic beads (MBs) to fabricate MB–CP1CP2 
conjugate. 
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155) immobilization on the gold screen printed 
electrode (Au-SPE), followed by the (2) non-specific 
binding blockage with mercaptosuccinic acid and (3) 
miRNA hybridization. 
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Table I: Electrochemical biosensors for miRNA detection (Cont.). 
a)Multi-walled Carbon Nanotubes; b) Peptide Nucleic Acid; c) Locked Nucleic Acid; d) Quantum Dots; e) 
Glassy Carbon Electrode; f) Cyclic Voltammetry; g) Electrochemical Impedance Spectroscopy; h) 
Tetramethylbenzidine; i) Horseradish Peroxidase; j) DNA Tetrahedral Nanostructure; k) Gold Electrodes; 
l) Amperometry; m) Gold nanoparticles; n) Screen Printed Carbon Electrode; o) Square Wave 
Voltammetry; p) Graphene Oxide.   
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 The synthetic DNA probes, being complementary with 
iRNA-24, were immobilized on MWCNT-modified 
glassy carbon electrodes by covalent cross-
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an interpenetrated network of carbon nanotubes and 
electroactive polymer. The nanostructured polymer film 
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cathodic potential domain from the quinone group 
embedded in the polymer backbone. 
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Table I: Electrochemical biosensors for miRNA detection (Cont.). 
q) Indium tin oxide; r) Differential pulse voltammetry; s) Screen-Printed Gold Electrode 
 
 
I.1.3.3.3. Optical biosensors 
Optical biosensors are an alternative to electrochemical-based devices. These 
 biosensors are light-based sensors that detect changes in specific wavelengths of 
light. The transducer can measure luminescence, fluorescence, colorimetry, or 
interferometry based phenomenon. The optical biosensors described so far in the 
literature for miRNAs have been summarized in table II. 
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Star trigon structure/endonuclease/Methylene Blue. 
Glassy carbon electrode covered with gold 
nanoparticles (AuNPs) mediated by poly(diallyldi-
methylammonium chloride). 
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Nanoparticles catalyze oxidation of hydrazine. The 
nanoparticle tags, isoniazid-capped 
OsO2nanoparticles, are brought to the electrode 
through a condensation reaction in order to 
chemically amplify the signal. 
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An electrochemical ELISA-like amplification 
strategy was set up using a secondary antibody 
conjugated to horseradish peroxidase (HRP). 
Hydroquinone is oxidized into benzoquinone by the 
HRP/H2O2 catalytic system. In turn, benzoquinone is 
electroreduced into hydroquinone at the electrode. 
The catalytic reduction current is related to HRP 
amount immobilized on the surface, which itself is 
related to miRNA. 
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Optical transducers convert changes in wavelengths in response to analyte recognition 
into an electrical/digital readout. Photonic crystal biosensors are a newly emerging class 
of biosensors that use an optical transducer. The photonic crystal sensor is designed to 
capture light from very small areas or volumes, allowing for greater sensitivity of 
measurement, and then transmitting that light into a high electromagnetic field for 
display. By measuring the light reflected by the crystal, this technique can detect when 
and where cells or molecules bind to or are removed from the crystal surface (Table II) 
(Jamali et al., 2014). 
 
Table II: Optical biosensors for miRNA detection. 
a) Quantum Dots; b) Graphene Oxide. 
 
Analysing tables I and II, it can be seen that electrochemical miRNA biosensors have 
impressive sensitivity, ranging from attomolar (aM) - nanomolar (nM) levels. For 
example, an electrochemical biosensor with nano-structured electrode exhibited an LOD 
of 10aM. In addition to millimetre scale biosensor designs, nano-scale electrochemical 
miRNA biosensors are being currently investigated as potential miRNA biosensors 
(Bourigua, Maaref, Bessueille, & Renault, 2013). For example, nanowires and nanopores-
based sensors displayed LODs of 1 fentomolar (fM) and 100 fM, respectively. The major 
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drawback of nano-scale devices is low sensor mass transfer rates which increases the 
time-to-results. Nano-scale biosensing approaches are promising as high sensitivity and 
multiplexing capability have been demonstrated.  
However, LOD optical miRNA biosensors range from nM-fM levels. For example, 
surface plasmon resonance in silicon micro-rings has been investigated, displaying an 
LOD near 1nM, albeit with excellent signal-to-noise ratio suggesting higher sensitivity 
could be achieved (Koyun, Ahlatcıoğlu, & İpek, 2012). 
 
I.1.4. Objectives  
The main goal of this thesis targets two different approaches. Firstly, a systematic review 
in order to identify the miRNAs related to breast cancer for subsequent application in 
biosensing device. The systematic revision was performed according to systematic 
reviews guidelines in order to establish the overall diagnostic accuracy of the 
measurement of miRNA in the diagnosis of breast cancer.  
The second approach consisted in the development of a low cost sensing-platform based 
on thiolated anti-miRNA immobilization in a gold screen printed electrode (Au-SPE) 
surface for fast screening miRNA-155 in point-of-care.  
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II. CHAPTER 
II.1. Experimental & Methods 
II.1.1. Systematic revision 
The systematic revision approach is linked to the results presented in chapter III.2. The 
database used in order to determine most frequent miRNA targets were PubMed, 
MiRbase.org and PRISMA.org. Multiple Boolean descriptors associated to the Meshterus 
were used in this research work.  
Each study was considered eligible for inclusion if it met the following inclusion criteria: 
(i) need to be published in English; (ii) include clinical trials on evaluation of miRNAs in 
the diagnosis of breast cancer; (iii) each group contained more than 10 patients. Finally, 
for data extraction the articles included author, publication year, state of study, diagnostic 
standard, patient number, specimen, test method, miRNA expression signature and 
methodological quality. The biological function of each miRNA was retrieved from 
MirBase.org. 
 
II.1.2. Biosensor assay 
 
II.1.2.1. Apparatus  
The electrochemical measurements were performed with a potentiostat/galvanostat from 
Metrohm Autolab, PGSTAT320N, controlled by NOVA 1.11 software. The Au-SPEs 
were purchased from DropSens (DS-C220AT). The Au-SPEs were interfaced in switch 
box from DropSens. 
UV-Vis spectra (200-800 nm) were recorded on an Evolution 220 UV-visible 
spectrophotometer (Thermo Scientific) for obtaining the spectral data for each solution 
(Anti-miRNA155, miRNA-155; and mixture of both) and spectral range between 220 and 
300 nm. 
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The morphological analysis of biosensor was performed by atomic force microscopy 
(AFM) in tapping mode. Surface characterization studies were conducted only on planar 
gold surfaces employed in regular surface plasmon resonance (SPR) measurements. 
The measurements were conducted in tapping mode (Veeco Metrology Multimode, 
Nanoscope IVA). The analysis of AFM images from tapping mode was obtained through 
nanoscope software.  
 
II.1.2.2. Electrochemical Procedures 
All electrochemical studies, including cyclic voltammetry (CV), electrochemical 
impedance spectroscopy (EIS) and square wave voltammetry (SWV) were performed in 
5.0×10-3 M of [Fe(CN)6]
3- and 5.0×10-3 M of [Fe(CN)6]
4-, prepared in PBS buffer pH 7.4, 
used as redox probe. All electrochemical assays were conducted in triplicate. 
For CV assays, the potential was scanned from -0.5 to +0.5 V, at 50 mV/s. The EIS assays 
were performed at a formal potential of +0.14V, using a sinusoidal potential perturbation 
with amplitude 0.01V, and 50 frequency values, logarithmically distributed over a 
frequency range of 0.1 to 100000 Hz. The EIS data was fitted to a Randles equivalent 
circuit using 1.11 Nova Software from Autolab. In SWV studies, the potential range was 
from -0.2 to +0.8 V with a frequency of 25Hz and the step height of to 50mV.  
The calibration curve/hybridization was performed for miRNA-155 concentrations 
ranging 1fM to 10nM prepared in Tris buffer, pH 7.4, and human blank synthetic serum 
(ranging from 0.00001fM to 10nM). The LOD was calculated as +3σ, where  was the 
average value of EIS or SWV of blank signals (obtained in the absence of miRNA-155) 
and σ known standard deviation of EIS or SWV blank signals (Harvey, 2000). 
Selectivity studies were conducted by competitive assay between miRNA-155 with two 
different species that can be found in biological fluids: BSA (0.30 µg/mL) and CA-15.3 
(30 U/mL). All assays were conducted in triplicate.  
  17   
III. CHAPTER  
III.1. Results and Discussion 
III.1.1. Systematic revision 
The first attempt to retrieve information from scientific evidences linking miRNA to 
breast cancer in literature made use of meta-analysis. Due to lack of data and non-
response from many authors, most information was retrieved from a systematic review 
approach. This information was tabulated (Table I in section III.2.4) and discussed, 
describing clinical features, author, specimen, number of patients, testing method, 
targeted miRNAs, and biological features of each MIR. In this systematic review, only 
studies describing MIR-145, MIR-155 and MIR-181 were considered, due to their high 
frequency in most reported papers. Also, the analysis of miRNAs by means of quantitative 
reverse transcription PCR (qPCR) was included. The information combining the miRNA 
involved in breast cancer and its signalling pathways and genes was also tabulated and 
discussed. All these results are detailed next, in section III.2.4, containing the 
corresponding submitted paper. 
 
III.1.2. Biosensor assay 
The construction of the biosensor relied in three steps. The first step consisted in covalent 
attach of the thiolated anti-miRNA155 probes on an Au-SPE surface. Next, the non-
specific binding was blocked with mercaptossucinic acid (MSA). The third step consisted 
in hybridization with miRNA-155, by incubation on Au-SPE with different 
concentrations at 37ºC. The thiolated anti-miRNA155 probe had a complementary 
sequence to the target miRNA155.The chemical modifications of the Au-receptor surface 
were followed by electrochemical measurements as CV, EIS and SWV.  
The overall performance of the biosensor was described in the section III.3. It includes 
calibration curves, selectivity study, and miRNA assays in human serum samples and in 
cell-line extracts. 
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The biosensor provided a sensitive detection of miRNA-155 from 10.0 aM to 1.0 nM with 
an LOD of 5.7 aM in human serum samples. Good results were obtained in terms of 
selectivity towards proteins present in human serum. The regeneration capability of the 
biosensor was evaluated and performed successfully. The last study consisted in miRNA 
assay with spiked samples of blank human serum. The sensor showed overall relative 
errors <10%.  
The miRNA assay was performed also with cell-line extracts (cell line, MCF-7) that 
contained miRNA-155. MCF-7 breast cancer cell line is the most studied human breast 
cancer cell line in the world and is related with miRNA-155 (Lee, Oesterreich, & 
Davidson, 2015). The performance of the biosensor was tested also in extracts from 
melanoma cell-lines, acting as negative control (line cell without miRNA-155, B16F10).  
 
Figure 3: EIS measurements for different cell lines. (A) MCF-7 and (B) B16F10. 
 
According to literature, the overexpression of miRNA-155 is linked to the cell growth in 
MCF-7 cell-line (Zhang, Zhao, & Deng, 2013). Different dilution degrees of the cell-line 
extracts were used, in order to evaluate the effect of the sample matrix on the sensor 
surface. Specifically, MCF-7 (Figure 3A) and B16F10 (Figure 3B) were tested for 100× 
and 1000× dilutions.  
As can be seen in the Figure 3, only cell line with miRNA155 promoted an increase in 
the diameter of the semicircle of the Nyquist. This was due to an electron transfer 
resistance increase, caused by the hybridization of miRNA155 into its complementary 
oligonucleotide. Such hybridization generated an increase of the density of negative 
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charges over the sensory surface, coming from the phosphate backbone of the hybridized 
oligonucleotides, thereby hampering the surface electron transfer properties from a 
standard Fe(CN)6
3-/4- redox probe solution (S. Wu et al., 2015). No change in the diameter 
of the semicircle were observed with the negative control B16F10 (Figure 3B), meaning 
that the normal composition of cell extracts would not interfere, even if such extracts 
contain biomolecules expressed by other cancer cells besides breast cancer. These results 
evidenced the high selectivity of the biosensor towards miRNA155. 
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III.2. Role of miR-145, miR-155 and miR-181a in Breast Cancer  
Systematic Review 
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III.2.1. Abstract 
 
Objective: MicroRNAs have been report to be overexpressed in breast cancer patients. 
The aim of this systematic review is to identify which miRNAs are related to Breast 
Cancer. 
 
Methods: The present study was performed according to Systematic Reviews guidelines 
in order to establish the overall diagnostic accuracy of the measurement of microRNA in 
the diagnosis of breast cancer. To identify studies eligible for systematic review in the 
PubMed citations. 
 
Results: The present systematic review of 14 studies comprises 1897 patients available 
for analysis. Regarding the systematic review were included studies that addressed the 
three types of most described microRNAs in breast cancer (miRNA-155, miRNA-145, 
miRNA-181a). Also, has been described the microRNA involved in breast cancer and 
signaling pathways for each miRNA, and also genes that are involved in these miRNA.  
 
Conclusion: MiRNA-155, 145 and 181a play an important role in breast cancer. These 
three miRNA are those that are more frequent and have more scientific evidence about 
their work, genes that act at the level of the carcinogenesis of breast cancer. 
 
Key words: miRNA-155, miRNA-145, miRNA-181a, Breast cancer. 
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III.2.2. Introduction 
Breast cancer is a prevalent disease, accounting for significant morbidity and mortality 
with a worldwide incidence of over 1,400,000 women (Taplin et al., 2008). Breast cancer 
is the most frequent cancer among women and the second leading cause of cancer death 
in women in Europe and North America and its incidence is steadily increasing. 
Currently, mammography is the standard screening tool worldwide, nevertheless this 
technique is not absent of limitations and is associated with substantial over diagnosis as 
well as a high false-positive rate (Taplin et al., 2008). About 3% of the population 
screened annually with mammography will present abnormalities, but of those 65% will 
be false positives (Langagergaard et al., 2013). In addition, small cancers are easily 
missed, especially in younger women due to denser breast tissue. Therefore, there is a 
need for highly sensitive and specific minimally invasive biomarker based assays for 
early detection of breast cancer, alone or in combination with mammography. 
MicroRNAs (miRNA) have been recently describe as potential new diagnostic 
biomarkers not only for of breast cancer but also for other cancers (Langagergaard et al., 
2013).  
MiRNAs are small non-protein-coding RNA molecules, with a length of 18-25 
nucleotides and act on the regulation of gene expression, and are fundamental in many 
cellular processes, such as differentiation, proliferation, apoptosis and metabolic 
homeostasis by modulating the expression of their target genes through cleaving mRNA 
molecules or inhibiting their translation (Jeffrey, 2008; Ryan, Robles, & Harris, 2010). 
Also control a wide range of pathological processes, including programmed cell death, 
oncogenesis and metastasis. The first step of biogenesis (Figure 1) of miRNA starts in 
nucleus with the gene transcription from RNA polymerase II, which produces a primary 
miRNA (Pri-miRNA). This transcript possesses a hairpin structure and is cleaved 
afterwards by Drosha (RNA polymerase 3) originating a precursor of mature miRNA 
called Pre-miRNA, with approximately 70 nucleotides. Exportin5 quickly exports pre-
miRNA to cytosol. In the cytosol, the Pre-miRNA is processed by DICER, originating a 
double-ribbon miRNA with approximately 22 nucleotides. The previous product is then 
incorporated in a multimeric complex known as RISC (RNA-Induced Silence Complex). 
Within this complex, only one of the chains of miRNA will remain and it will be 
responsible for the post-transduction expression of target genes. Through the RISC 
complex we will obtain the pairing between the miRNA and the homolog target mRNA, 
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through reverse base complement. Therefore, when there is total pairing between both 
chains of RNA, RNA degradation occurs, but, on the other hand, when there is only partial 
pairing, translation’s repression occurs followed by posterior degradation of mRNA (He 
& Hannon, 2004). 
 
Figure 4: The current model for the biogenesis and post-transcriptional suppression of microRNAs.  In 
nucleus, the miRNA gene is transcript from RNA polymerase II, which produces a primary miRNA, pri-
microRNA (pri-miRNA). The pri-microRNA transcripts are first processed into ~70-nucleotide pre-
miRNAs by Drosha inside the nucleus.  Pre-miRNA is quickly exported by Exportin 5 to cytosol. In 
cytoplasm the Pre-miRNA is processed by Dicer thus originating a double-ribbon miRNA.This product 
is unwind then incorporated in complex RISC.  Through the RISC complex it will obtain the pairing 
between the miRNA and the homolog target mRNA, through reverse base complement.  This 
subsequently acts on its target by translational repression or mRNA cleavage, depending, at least in part, 
on the level of complementarity between the small RNA and its target. 
 
Generally, a tumor suppressor miRNA typically blocks the expression of an oncogene 
mRNA. Conversely, miRNA oncogenes (also known as oncomir) block expression of 
tumor suppressor genes, leading to increased risk of tumor formation (Di Leva & Croce, 
2010; Li et al., 2009; Wijnhoven, Michael, & Watson, 2007; Zhang, Pan, Cobb, & 
Anderson, 2007). 
Aberrant expression levels of miRNAs have been observed in many solid tumors, 
including breast cancer. Furthermore, miRNAs and their targets appear to form a complex 
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regulation network. A single miRNA can regulate several mRNAs and a single mRNA 
may be targeted by a number of different miRNAs. Approximately one third of all human 
genes encoding proteins that are regulated by miRNA based computational predictions 
(J. Lu et al., 2005). Thus, measurement and quantification of the miRNA can translate in 
a more reliable method and less invasive for the presence of cancer. In addition, their 
expression provides information about the origin of the tumour and allows classifying the 
degree of tumour aggressiveness (Jeffrey, 2008; Ma, Teruya-Feldstein, & Weinberg, 
2007; Zhang et al., 2007). One of the most important advantages of using circulating 
miRNAs as biomarkers, apart from being easily measured in blood samples, is their 
remarkable stability in plasma and serum, where they are most likely protected from 
RNase degradation due to their binding to Argonaut proteins (Arroyo et al., 2011; 
Mitchell et al., 2008). However, it remains unclear whether a particular combination of 
circulating miRNAs is superior to single miRNAs as a diagnostic test in early breast 
cancer. Different correlations have been described at very earlier stages between miRNA 
and several types of cancers, in which they present an abnormal expression levels. In 
breast cancer, the levels of expression of several miRNAs are significantly different 
between normal tissue and the tumour, and also between breast cancers with different 
molecular subtypes with a different prognosis, showing the different responses to 
endocrine therapy (Ma et al., 2007). As a result, we have proposed to perform a systematic 
review, in order to understand the relationship of miRNA and breast cancer. Furthermore, 
we propose to evaluate the diagnostic value of some miRNAs as biomarker. 
 
III.2.3. Material and methods 
We performed a systematic review regarding the presence of particular type of miRNA 
and breast cancer.  
III.2.3.1. Search strategy and study selection 
To identify studies eligible for systematic review, used citations in the PubMed, were 
surveyed combinations of several MeSH terms as “Breast cancer”, “miRNA” and 
“diagnosis”. A study was included if it met the following inclusion criteria: (i) published 
in English; (ii) e-clinical studies on evaluation of miRNAs in the diagnosis of breast 
cancer; (iv) each group contains more than 10 patients.  
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Figure 5: Flow chart of the search of systematic review. 
 
III.2.3.2. Data extraction 
Data retrieved from these articles included author, publication year, state of study, 
diagnostic standard, patient number, specimen, test method, miRNA expression signature 
and methodological quality. 
III.2.3.3. On-line databases 
To conclude the systematic reviews, as well assessing which are the most frequent 
miRNA target’s, several online databases were used, namely PubMEd and Mirbase.org. 
 
III.2.4. Results 
A table was developed to gather information more synthesized. Clinical characteristics of 
the works included were extracted the present study and the listed in Table I. In this table, 
the author, specimen, patients number, test method, the miRNAs that were analyzed, and 
finally, relevant results were reported for each study. In the present systematic review of 
14 studies comprised 1897 patients available for analysis, however, only were considered 
studies describing miRNA-145, miRNA-155, and miRNA-181a due to their frequency 
on most studies. Also, miRNAs where analysed by means of quantitative reverse 
transcription PCR (qPCR).  
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 Table III: Systematic review is of miRNAs related to Breast cancer. 
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miRNA-122 
miRNA-375 
MiRNA-375 and miRNA-122, exhibited strong correlations 
with NCT (neoadjuvant chemotherapy) response and relapse 
with metastatic disease. Also, higher levels of circulating 
miRNA-122 specifically predicted metastatic recurrence in 
stage II-III BC (Breast Cancer) patients. 
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 miRNA-10b 
miRNA-34a 
miRNA-141 
miRNA-155 
The significant increase of miRNA-10b, miRNA34a and 
miRNA-155 concentrations in the peripheral blood of breast 
cancer patients and the observed associations with tumor 
progression. Although the levels of miRNA-141 did not 
markedly change in the blood of patients with metastatic 
disease in comparison to patients with primary breast cancer. 
In tumor cell lines, the concentrations of the four miRNAs 
differed strikingly from those in the micrometastatic tumor 
cell lines. 
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miRNA-215 
miRNA-299-
5p 
miRNA-411 
miRNA-452 
Overexpression of miRNA-215, miRNA-299-5p, miRNA-
411, and miRNA-452 in normal breast samples, in addition 
to the fact that miRNAs have a proven stability in blood 
samples.  In other words, observe the reduction of miRNA 
expression was particularly obvious in serum samples from 
patients with untreated metastatic breast cancer.  
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miRNA-15a 
miRNA-18a 
miRNA-107 
miRNA-133 
miRNA-139 
miRNA-143 
miRNA-145 
miRNA-365 
miRNA-425 
Novel circulating 9-miRNA signature that discriminates 
between serum from early-stage, estrogen receptor (ER)-
positive, breast cancer patients and healthy control subjects.  
Down-regulation of miRNA-145 in serum of women with 
breast cancer compared to normal controls, miRNA-133a 
and miRNA-143 were up-regulated, higher expression of 
miRNA-107 in breast cancer vs. normal tissue. Low levels 
of miRNA-139-5p and high levels of miRNA-425 were 
observed in breast cancer vs. adjacent normal tissue, 
miRNA-365 was found to be more highly expressed in 
breast cancer tissue. 
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miRNA-182 
MiRNA 182 was also overexpressed in the BC tissues 
compared with the para-carcinoma tissues. The serum levels 
of miR‑182 in the ER-positive patients were considerably 
lower compared with those in the ER‑negative patients. The 
serum levels of miRNA-182 in the progesterone receptor 
(PR)-positive patients were also found to be lower 
compared with those in the PR‑negative patients. (P
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 miRNA-195 
let 7a 
miRNA-10b 
Elevated circulating miRNA-195 was found to be breast 
cancer specific and could differentiate breast cancer from 
other cancers and from controls with a sensitivity of 88% at 
a specificity of 91%. A combination of three circulating 
miRNAs, including miRNA-195, further enhanced the 
discriminative power of this test for breast cancer to 94%.  
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miRNA-155 
Showed that miRNA-155 was markedly increased in sera 
from breast cancer patients compared with normal controls. 
Showed a declined trend of miRNA-155 after surgery and 
chemotherapy, which raises the possibility to use it as an 
indicator for treatment response. 
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Table III: Systematic review is of miRNAs related to Breast cancer (cont.). 
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 miRNA-145 
miRNA-451 
 
Showed that a combination of miRNA-145 and miRNA-451 
was the best biomarker in discriminating breast cancer from 
healthy controls and all other types of cancers.  MiRNA-145 
have reduction of plasma level in breast cancer patients, in 
contrast miRNA-451 have elevation in plasma of breast 
cancer. 
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 miRNA-29a, 
miRNA181a 
miRNA-652 
MiRNA-29a, miRNA-181a, miRNA-652, profile of three 
circulating tumor-associated miRNA biomarkers for breast 
cancer are identified which in combination provide a 
sensitivity and specificity profile which exceeds that of 
several current clinical biomarkers.  
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miRNA-205 
miRNA-155 
MiRNA-205 was down-regulated in BC patient serum while 
miR-155 was up-regulated. High expression of miRNA-155 
was associated with clinical stage, molecular type, Ki-67 
and p53 in BC patients. Showed that ectopic expression of 
miRNA-205 significantly inhibits cell proliferation and 
promotes apoptosis. MiRNA-205 was down regulated and 
miRNA-155 was up-regulated in BC patient serum. 
MiRNA-155 was positive correlated with clinical stage and 
ki-67 and negatively correlated with p53 status. 
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 miRNA-155 
miRNA-31 
 
MiRNA-31, miRNA-155 expression in tissue samples was 
consistent with that in plasma samples, indicating that the 
miRNA-155 level is a direct reflection of miRNA-155 
expression in cancerous tissues. 
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 miRNA-18a 
miRNA-181a 
miRNA-222 
Overexpression of the 3 highest expressing miRNAs:  
miRNA-18a, miRNA-181a, and miRNA-222. 
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miRNA-155 
miRNA-125b 
miRNA-145 
miRNA-21 
miRNA-155 
RNA expression could clearly separate normal versus 
cancer tissues, with the most significantly deregulated 
miRNAs being miRNA-125b, miRNA-145, miRNA-21, 
and miRNA-155. 
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miRNA-181a 
MiRNA-181a as a predictive biomarker for breast cancer 
metastasis and patient survival, and consequently, as a 
potential therapeutic target in metastatic breast cancer. 
MiRNA-181a expression was dramatically and selectively 
upregulated in metastatic breast tumors, particularly triple-
negative breast cancers, and was highly predictive for 
decreased overall survival in human breast cancer patients. 
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Once you know what the miRNA that appear more often, we prepare another table in order 
to know the miRNA involved in breast cancer and signalling pathways for each miRNA, and 
also genes that are involved in these miRNA.  
 
III.2.4.1. miRNA 145 
III.2.4.1.1. Role of miRNA 145 in Breast Cancer 
MiRNA-145, this is known as a tumor suppressor in numerous human cancers, exhibits an 
inhibitory role in tumoral angiogenesis, cell growth and invasion and tumor growth through 
the post-transcriptional regulation of the novel targets N-RAS and VEGF-A, and may plays 
important inhibitory role in breast cancer malignancy by targeting these genes, early 
manifestation of altered. Studies showed that miRNA-145 is a putative tumor suppressor 
gene that is down regulated in several types of tumors and inhibits cell growth by targeting 
c-Myc and Insulin receptor substrate 1 (IRS-1). Furthermore, miRNA-145 is reported to 
target the pluripotency factors octamer-binding transcription factor 4 (OCT4), SOX2,( (SRY 
(Sex Determining Region Y)-Box 2) and KLF4 (Kruppel-like factor 4) and plays a key 
regulator in human stem cells (Singh & Mo, 2013).  
III.2.4.1.2. Role of miRNA 145 in other signaling pathways 
MiRNAs function to regulate the expression levels of other genes by a several mechanisms. 
Michael et al. (2003) subsequently verified expression of mir-hsa-145, and demonstrated 
significantly reduced levels of the miRNA in precancerous and neoplastic colorectal tissue. 
The mature sequence shown here represents the most commonly cloned form from large-
scale cloning studies. Also, this miRNA is involved in the control of several groups of genes 
like transcription factors, coagulation factors, zinc finger CCCH-type containing 11A, 
gamma-aminobutyric acid A (GABA(A))  receptor-associated protein like 1, integrin, 
calmodulin, interferon gamma receptor 2 (Cui, Wang, & Chen, 2014; Michael, O'Connor, 
Pellekaan, Young, & James, 2003). 
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III.2.4.2. miRNA 155 
III.2.4.2.1. Role of miRNA 155 in Breast Cancer 
MiRNA-155 is overexpressed in breast cancer, thus being considered as an oncomir. 
Deregulation of their expression is involved in numerous pathological processes and 
oncogenic signaling. Also, showed that miRNA-155 was markedly increased in sera from 
breast cancer patients compared with normal controls. Furthermore, miRNA-155 expression 
was inversely correlated with ER and PR expression, regardless of human epidermal growth 
factor receptor 2 (HER-2) status. These findings suggest that miRNA-155 expression is 
deregulated in breast cancer and is involved in the oncogenesis of breast tumors. High 
expression of miRNA-155 was associated with clinical stage, molecular type, Ki-67 and 
tumor protein (p53) in breast cancer patients (Mattiske, Suetani, Neilsen, & Callen, 2012). 
III.2.4.2.2. Role of miRNA 155 in other signaling pathways 
MiRNA-155 plays an important role in various physiological and pathological processes. 
Exogenous molecular control in vivo of miR-155 expression may inhibit malignant growth, 
viral infections, and attenuate the progression of cardiovascular diseases. Also, miRNA-hsa-
155 is regulates human HL-60 leukemia cells. MiRNA-hsa-155 resides in the non-coding 
BIC transcript (EMBL:AF402776), located on chromosome 21. Eis et al (2005) confirm that 
miRNA-155 is processed from the BIC transcript in human, and demonstrate elevated 
expression of miR-155 in lymphoma samples. The mature sequence shown here represents 
the most commonly cloned form from large-scale cloning studies. This miRNA is involved 
in the control of several groups of genes like protocadherin alpha, ATPases, transcription 
factors, RNA polymerases, hormones, and nucleases zinc finger transcription factors and 
zinc finger. 
III.2.4.3. MiRNA 181a 
III.2.4.3.1. Role of miRNA 181a in Breast Cancer 
MiRNA-181, also an oncomir, is considered a predictive biomarker for breast cancer 
metastasis and patient survival. Consequently, mir-181a is a potential therapeutic target in 
metastatic breast cancer. MiRNA-181a expression was dramatically and selectively up 
regulated in metastatic breast tumors, particularly triple-negative breast cancers, and was 
highly predictive for decreased overall survival in human breast cancer patients. Another 
study showed that miR-181a functioned as a tumor suppressor by inducing apoptosis, 
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triggering growth inhibition and inhibiting invasion in glioma cells. If this is also the case in 
breast cancer, it raises the possibility that miRNA-181a could be exploited as a therapeutic 
intervention for breast (Bisso et al., 2013). 
III.2.4.3.2. Role of miRNA 181a in other signalling pathways 
This new class of genes has recently been shown to play a central role in malignant 
transformation. MiRNA are down regulated in many tumors and thus appear to function as 
tumor suppressor genes. The mature products miRNA-181a, miRNA-181b, miRNA-181c or 
miRNA-181d are thought to have regulatory roles at posttranscriptional level, through 
complementarity to target mRNAs. Furthermore, this miRNA is also involved in the control 
of many genes as transcription factors, ATases, importin 8, ataxia telangiectasia mutated, 
breast cancer 1 (BRCA1)  associated protein, insulin-like growth factor 2 mRNA binding 
protein 2 (Hayes & Lewis-Wambi, 2015). 
 
III.2.5. Discussion 
The diagnosis of breast cancer is crucial for implementing effective therapy so that the 
diagnostic tools should be as sensitive and specific as possible. Thus, the study of new types 
of biomarkers is essential in order to circumvent the shortcomings in the current diagnostic 
methods. Over the past years, several authors have been working with miRNA as possible 
biomarkers of breast cancer. Since dysfunction of miRNA in breast cancer was first reported 
in 2005, there have been many studies on the expression of several miRNAs and their roles 
in breast cancer. However, since late 2009, several groups reported on circulating miRNAs 
as markers for breast cancer detection. Most of these studies focused on comparing 
circulating levels of miRNAs in cancer patients to that of healthy controls, while only few 
studies investigated alterations in miRNA levels after surgery of early stage breast cancer 
(Kodahl et al., 2014). In current systematic review, we identified the three most frequent 
miRNA in breast cancer that are more investigated, namely, miRNA-155, 145 and 181a.  
Regarding miRNA-155 is overexpressed in breast cancer, and deregulation of their 
expression involved in numerous pathological processes and oncogenic signaling. It was 
revealed that the miRNA-155 expression levels in breast cancer tissues were significantly 
elevated compared with those in paired normal tissues. Furthermore, miRNA-155 expression 
was inversely correlated with ER and PR expression, regardless of HER-2 status. These 
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findings suggest that miRNA-155 expression is deregulated in breast cancer and is involved 
in the oncogenesis of breast tumors (Kodahl et al., 2014; Liu et al., 2013). 
Martin et al (2014) demonstrated that miR-155 expression increases tumorigenesis in vivo 
and determined miRNA-155 mediated transcriptome changes through next generation 
sequencing analysis. MiRNA-155 expression alters many signaling pathways, with the chief 
altered pathway being the mitogen-activated protein kinases (MAPK) signaling cascade and 
miR-155 induces shortening of target mRNA 3'UTRs and alternative isoform expression of 
MAPK related genes. In addition there is an observed increase in protein phosphorylation of 
components of MAPK signaling including extracellular signal-regulated protein kinases 1 
and 2  (ERK1/2) and activator protein 1 (AP-1) complex members (Fra-1 and c-Fos) as well 
as elevated gene expression of MAPK regulated genes Zeb1, Snail, Plaur, and SerpinE1 
(Martin et al., 2014). 
Roth et al (2010) relate the significant increase of miRNA-10b, miRNA-34a and miRNA-
155 concentrations in the peripheral blood of breast cancer patients and the observed 
associations with tumor progression. In primary and metastatic breast carcinomas, high 
transcript levels of miRNA10b were detected and associated with tumor progression. 
Overexpression of miRNA-10b in a non-metastatic breast cancer cell line induced invasion 
and metastasis. For example, knockdown of miRNA-34a by small interfering RNA 
significantly suppressed proliferation in the breast cancer cell line MCF-7, indicating that 
miR34a overexpression may be an acquired feature during carcinogenesis and support cell 
proliferation in breast tumors. Knockout mice, which do not express miRNA-155, showed 
that this miRNA played an important role in the immune system. In Hodgkin’s lymphoma 
diffuse B cell lymphoma and breast cancer miRNA-155 was highly expressed (Roth et al., 
2010). 
Cai et al (2015) related that miRNA-155 has been implicated in the induction of breast, lung 
and liver cancer, but its role in prostate cancer has not been investigated. In this study, 
demonstrated that the expression of miRNA-155 was upregulated in prostate cancer tissues 
and cell lines as determined by quantitative reverse transcription-polymerase chain reaction. 
Furthermore, overexpression of miRNA-155 promoted cell proliferation, as indicated by 
MTT assay. Flow cytometric analysis demonstrated that inhibition of miR-155 induced cell 
cycle arrest and promoted apoptosis in prostate cancer cells. In addition, western blot 
analysis indicated that annexin 7(ANX7) was significantly downregulated in prostate cancer 
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tissues and cells. A luciferase reporter assay indicated that ANX7 was a target of miRNA-
155, which suggested that miRNA-155 promoted the proliferation of prostate cancer cells 
by regulating ANX7 expression levels (Cai et al., 2015). 
Another way analysis is Bioinformatics and metabolomics analysis. Kim et al (2015) used 
this technology showed a novel role of miRNA-155 in cancer metabolism through the up-
regulation of thiamine in breast cancer cells. A bioinformatics analysis of miRNA array and 
metabolite-profiling data from NCI-60 cancer cell panel revealed thiamine as a metabolite 
positively correlated with the miRNA-155 expression level. They confirmed it in MCF7, 
MDA-MB-436 and two human primary breast cancer cells by showing reduced thiamine 
levels upon a knock-down of miRNA-155. To understand how the miR-155 controls 
thiamine level, a set of key molecules for thiamine homeostasis were further analyzed after 
the knockdown of miRNA-155. The results showed the expression of two thiamine 
transporter genes (SLC19A2, SLC25A19) as well as thiamine pyrophosphokinase-1 (TPK1) 
were decreased in both RNA and protein level in miRNA-155 dependent manner. Also, 
confirmed the finding by showing a positive correlation between miRNA-155 and thiamine 
level in 71 triple negative breast tumors and demonstrated a role of miRNA-155 in thiamine 
homeostasis and suggests a function of this oncogenic miRNA on breast cancer metabolism 
(Kim et al., 2015). 
Sun et al (2012) suggest that serum miRNA-155 is a potential biomarker to discriminate 
breast cancer patients from healthy subjects. For the first time, demonstrated a declined trend 
of miRNA-155 after surgery and chemotherapy, which raises the possibility to use it as an 
indicator for treatment response (Y. Sun et al., 2012). Also another study, reveal that the 
effects of miRNAs on the development of breast cancer drug resistance. Among them, miR-
155 takes part in a sequence of bioprocesses that contribute to the development of such drug 
resistance, including repression of forkhead box O3 (FOXO3), enhancement of epithelial-
to-mesenchymal transition (EMT) and MAPK signalling, reduction of RhoA, and affecting 
the length of telomeres (Yu et al., 2015).  
Liu et al (2012) used real-time PCR (qPCR) and analysed miRNA-205 and miRNA-155 in 
archived serum from 30 participants, 20 with breast cancer and 10 healthy people. MiRNA-
205 was down regulated in breast cancer patient serum while miRNA-155 was up regulated. 
Furthermore, also analysed the relationship between the expression levels of these two 
miRNAs and the clinic pathologic parameters of breast cancer patients. High expression of 
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miRNA-155 was associated with clinical stage, molecular type, Ki-67 and p53 in breast 
cancer patients. By contrast, they found no significant correlation between miRNA-205 and 
breast cancer patient clinic pathologic parameters. Functional analysis showed that ectopic 
expression of miRNA-205 significantly inhibits cell proliferation and promotes apoptosis. 
MiRNA-205 was down regulated and miRNA-155 was up regulated in BC patient serum. 
MiRNA-155 was positive correlated with clinical stage and ki-67 and negatively correlated 
with p53 status (Liu et al., 2013). 
Tsang et al (2015) used polymerase chain reaction (PCR)-based miR profiling was 
performed in a small mammary phyllodes tumours (PT) cohort to identify deregulated miRs 
in malignant PT. The purported roles and targets of these miRs were further validated. 
Unsupervised clustering of miRNA expression profiling segregated PT into different grades, 
implicating the miR profile in PT classification. Among the deregulated miRs, miR-21, miR-
335 and miR-155 were validated to be higher in malignant than in lower-grade PT in the 
independent cohort by quantitative PCR (qPCR) (P ≤ 0.032). Their expression correlated 
with some of the malignant histological features, including high stromal cellularity, nuclear 
pleomorphism and mitosis. Subsequent analysis of their downstream proteins, namely 
phosphatase and tensin homolog (PTEN) for miRNA-21/miRNA-155 and retinoblastoma 
(Rb) for miRNA-335, also showed an independent significant negative association between 
miRNA and protein expression (Tsang JY, 2015). 
Lu et al (2012) purpose of the present study determined the tissue and plasma levels of 
miRNA-155 and miRNA-31 in 67 patients with invasive intra-ductal breast cancer and their 
correlation with the clinic pathological characteristics. Used a quantitative real-time-PCR 
(qPCR) assay, it was demonstrated that the plasma levels of miRNA-155 and miRNA-31 in 
patients were 6- and 5-fold higher than those in healthy individuals, respectively. In 
cancerous tissues, miRNA-155 expression levels were 5-fold higher compared with those in 
non-cancerous tissues, whereas no difference was observed with miRNA-31 expression. The 
expression levels of miRNA-155, but not miRNA-31, were inversely correlated with ER and 
progesterone receptor PR expression. The tissue and plasma levels of miRNA-155 and 
miRNA-31 were not correlated with HER-2 expression levels. Furthermore, high levels of 
plasma miRNA-155 and miRNA-31 were identified in the tumors of TNM stage II. Also, 
miRNA-155 was mainly expressed in patients with a pathology score of 3 for ER or PR 
expression; miR-31 expression was higher in patients with a pathology score of 2. These 
results suggest that miRNA-155 and miRNA-31 are differentially expressed in breast cancer 
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patients. Their correlation with the clinic pathological characteristics may aid the diagnosis 
and treatment of invasive intra-ductal breast cancer (J. Lu et al., 2005; Z. Lu et al., 2012).  
Recent studies indicate that a series of isomiRs can be yielded from a miRNA locus, and 
these physiological miRNA isoforms have versatile roles in miRNA biogenesis, so the Wu 
et al (2015), performed a comprehensive analysis of miRNAs at the miRNA and isomiR 
levels in Breast Cancer using next-generation sequencing data from The Cancer Genome 
Atlas (TCGA). Abnormally expressed miRNA (miRNA-21, miRNA-221, miRNA-155, 
miRNA-30e and miRNA-25) and isomiR profiles could be obtained at the miRNA and 
isomiR levels, and similar biological roles could be detected. IsomiR expression profiles 
should be further concerned, and especially isomiRs are actual regulatory molecules in the 
miRNA-mRNA regulatory networks. The study provides a comprehensive expression 
analysis at the miRNA and isomiR levels in Breast Cancer, which indicates biological roles 
of isomiRs (Wu et al., 2015) 
Igglezou et al (2014) measured RNA levels of three microRNAs with tumorigenic or 
angiogenic potential (miRNA-155, miRNA-195, and miRNA-21) in blood samples taken 
from patients with early breast cancer, both preoperatively and postoperatively. The results 
that showed elevated postoperative levels of miRNA-195 were detected only in patients who 
developed early tumor relapse and that miRNA-155 levels tended to increase three days 
postoperatively and fell below baseline one month post-surgery (p<0.05).  The results of this 
pilot study indicate a possible involvement of miRNA-155 in surgery-induced angiogenesis 
and potential prognostic significance of high postoperative levels of circulating miR-195 in 
patients with breast cancer (Igglezou, Vareli, Georgiou, Sainis, & Briasoulis, 2014) 
Another miRNA that is very involved in signaling pathways in breast cancer is miRNA-145, 
this is known as a tumor suppressor in numerous human cancers, exhibits an inhibitory role 
in tumoral angiogenesis, cell growth and invasion and tumor growth through the post-
transcriptional regulation of the novel targets N-RAS and vascular endothelial growth factor 
A (VEGF-A), and may plays important inhibitory role in breast cancer malignancy by 
targeting these genes, early manifestation of altered. Also this is miRNA that is a putative 
tumor suppressive gene that is down-regulated in several types of tumor and inhibits cell 
growth by targeting c-Myc and IRS-1.  
Furthermore, miRNA-145 is reported to target the pluripotency factors OCT4, SOX2, and 
KLF4 and plays a key regulator in human stem cells.  MiRNA-145 expression in atypical 
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hyperplasia and carcinoma in situ lesions in breast cancer suggests that this miRNA may 
have a potential clinical application as a novel biomarker for early detection (Ng et al., 2013; 
van Schooneveld et al., 2012).  
Muthiah et al (2015), delivery of therapeutic miRNA using nanoparticles enhances the 
chances of successful delivery and expression of genes at the target site. They used 
polysorbitol-mediated transporter (PSMT) in the cellular delivery of miRNA-145. The 
polysorbitol backbone possesses osmotic properties and leads to enhanced cellular uptake. 
PSMT delivers genes into cells by a caveolae-mediated endocytic pathway. Caveolae 
expression is usually altered in transformed cancer cells. Also, confirmed that miRNA-145 
delivered with PSMT has reduced the proliferation of cancer cells in in vitro efficiently when 
compared to control carrier. In vivo efficiency of the PSMT/miRNA-145 is to be confirmed 
and then move forward towards further steps in cancer treatment (Muthiah et al., 2015). 
Ekin et al (2015) used nanotechnology has the potential to facilitate the detection, diagnosis, 
and treatment of cancer cases. Successful delivery of nucleic acids into cancer cells with the 
use of nanoparticles would be a significant improvement for medical and cellular biology. 
The use of nanoparticle-based vehicles in clinical treatment is considerably important for 
treating genetic disorders. Gold nanoparticles (AuNPs) have been suggested as therapeutic 
delivery tools for cancer. Because miRNAs, which induce post-transcriptional gene 
silencing, are deregulated in cancer cells, they are also considered as strong candidates for 
cancer therapy applications. In prostate and breast cancer, miRNA-145, a well-known tumor 
suppressor miRNA, is strongly downregulated in tumor tissues compared to their 
corresponding normal tissues, and demonstrate the efficient of delivery of miR-145 to 
prostate/breast cancer cells. Also, they showed that delivery was more efficient when the 
AuNP-RNA-miRNA carrier complex was formed at an elevated temperature of 72 °C (Ekin, 
Karatas, Culha, & Ozen, 2014).  
Ng et al (2013) identified significant elevation of the miRNA-16, miRNA-21, and miRNA-
451 and significant reduction of miRNA-145 in the plasma of breast cancer patients. The 
combination of plasma miRNA-145 and miRNA-451 levels provided the best marker for 
breast cancer prediction. Also showed that the best combination of miRNA-451 and miRNA-
145 plasma levels are very specific to breast cancer and did not elevate in all other cancer 
types included in this study. Besides, elevation of plasma miRNAs has been detected in not 
only advanced stages of breast cancer but also early stages (pre-invasive stages) of breast 
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cancer such as ductal carcinoma in situ (DCIS) suggested that this marker might be useful 
for early diagnosis. Studies showed that miRNA-145 is a putative tumor suppressive gene 
that is down regulated in several types of tumors and inhibits cell growth by targeting c-Myc 
and IRS-1. Furthermore, miRNA-145 is reported to target the pluripotency factors OCT4, 
SOX2, and KLF4 and plays a key regulator in human stem cells (Ng et al., 2013). Recently, 
Sachdeva et al (2010) (Sachdeva & Mo, 2010) further characterized miRNA-145 in different 
cancer cell lines and found that miRNA-145 functions as a tumor suppressor in a cell type– 
specific manner. This report showed that miRNA-145 is a tumor suppressor affecting 
invasion and metastasis (van Schooneveld et al., 2012). 
Iorio et al (2014) compared normal breast tissue with human breast cancer. MiRNAs are 
also aberrantly expressed in human breast cancer. The overall miRNA expression could 
clearly separate normal versus cancer tissues, with the most significantly deregulated 
miRNAs being miRNA-125b, miRNA-145, miRNA-21, and miRNA-155. Results were 
confirmed by microarray and Northern blot analyses. It possible identify miRNAs whose 
expression was correlated with specific breast cancer biopathologic features, such as 
estrogen and progesterone receptor expression, tumor stage, vascular invasion, or 
proliferation index (Iorio et al., 2005). 
Sun et al (2014) compared to the normal control, a total of 21, 47, and 107 differentially 
expressed miRNAs were screened in DCIS, invasive and metastatic breast cancer, 
respectively. Specific differentially expressed miRNAs of the three subtypes were identified, 
including hsa-miRNA-99a and hsa-miRNA-151-3p for DCIS breast cancer, hsa-miRNA-
145 and hsa-miRNA-210 for invasive breast cancer, and has-miRNA-205 and has-miRNA-
361-5p metastatic breast cancer. Furthermore, 220, 43, 446, 307, 587 and 328 interaction 
pairs of the specific miRNA targets were predicted. Multiple GO functions and KEGG 
pathways were enriched with the miRNA targets and their interacted genes. Also, screened 
the most representative miRNAs of the three different subtypes of breast cancer, which may 
act as the putative markers in the diagnosis of different subtypes of breast cancer (E. H. Sun 
et al., 2014). 
Finally, miRNA 181a levels were up regulated in breast cancer patients compared with 
healthy controls, for that and therefore, this miRNA is considered to be a potential marker 
for breast cancer. MiRNA-181a may be useful in detecting certain carcinomas at early 
stages, particularly when the individuals are clinically asymptomatic for extended periods. 
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Also, another studies indicated the precise targets of miRNA-181a in breast cancer remain 
elusive, and it is unclear how miRNA-181a may be involved in tumor formation or how the 
levels relate to prognosis. MiRNA-181a expression level was lower in early stage breast 
cancer, leading to speculation that the link between K-ras and miRNA-181a may play a role 
in the etiology of this malignancy. Another study showed that miRNA-181a functioned as a 
tumor suppressor by inducing apoptosis, triggering growth inhibition and inhibiting invasion 
in glioma cells. If this is also the case in breast cancer, it raises the possibility that miRNA-
181a could be exploited as a therapeutic intervention for breast (Guo & Zhang, 2012).  
McDermott et al identified four miRNAs (miRNA-29a, miRNA-181a, miRNA-223 and 
miRNA-652) with deregulated expression in the circulation of women with Luminal A-like 
breast cancer. MiRNA-181a and miRNA-652 were down regulated in Luminal A-like breast 
tumor tissue, while miRNA-29a was not. These findings support the hypothesis that 
circulating miRNA expression profiles may not act as a direct window on tumor activity and 
brings into question the mechanism by which they enter the blood stream, in addition to their 
functional role, if any, in the peripheral circulation. Also, miRNA-181a has previously been 
reported as being significantly under-expressed in the serum of women with breast cancer 
compared to healthy controls (McDermott et al., 2014). 
Godfrey et al (2013) showed miRNA-181a is believed to target the tumor suppressor gene 
programmed cell death protein 4 (PDCD4), which inhibits tumor neoplastic transformation. 
In breast cancer cell lines, miRNA-222 overexpression has been reported to be associated 
with tamoxifen resistance through targeting the cell cycle inhibitor p27 (Kip1). Also, they 
found two recent case control studies have provided evidence that both miRNA-222 and 
miRNA-181a are overexpressed in the serum of patients with breast cancer. One used 
sequencing by oligonucleotide ligation and detection (SOLiD) of serum samples obtained 
prior to surgery from 13 breast cancer cases compared with samples from 10 healthy controls 
and found 26 miRNAs that were overexpressed in cases, including miRNA-222 and miRNA-
181a (Godfrey et al., 2013). 
Taylor et al (2013) established one relationship with miRNA-181a and transforming growth 
factor β (TGF-β)–regulated “metastamir” that enhanced the metastatic potential of breast 
cancers by promoting epithelial-mesenchymal transition, migratory, and invasive 
phenotypes. Mechanistically, inactivation of miRNA-181a elevated the expression of the 
pro-apoptotic molecule Bim, which sensitized metastatic cells to anoikis. Along these lines, 
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miRNA-181a expression was essential in driving pulmonary micrometastatic outgrowth and 
enhancing the lethality of late-stage mammary tumors in mice. Finally, miRNA-181a 
expression was dramatically and selectively up regulated in metastatic breast tumors, 
particularly triple-negative breast cancers, and was highly predictive for decreased overall 
survival in human breast cancer patients. Collectively, their findings strongly implicate 
miRNA-181a as a predictive biomarker for breast cancer metastasis and patient survival, and 
consequently, as a potential therapeutic target in metastatic breast cancer (Taylor et al., 
2013). 
III.2.6. Conclusion  
The present systematic review suggests an important role of miRNA miRNA-155/145/181a 
in breast cancer. These three miRNA are those that are more frequent and have more 
scientific evidence about their work, genes that act at the level of the carcinogenesis of breast 
cancer.  
Regardless of the great number of studies in this field, performing additional research to 
clarify the role of miRNA in breast cancer seems critical, needed and potentially precious. 
This situation assumes an even bigger importance due to the fact that the current diagnostic 
tool for breast cancer, mammography is not totally reliable. Therefore, developing new 
potential biomarkers is essential, in a way that combining various methodologies will allow 
having a more preventing way to confirm breast cancer and thus, apply a better treatment to 
the patient. 
However, to prove that these miRNA are those with greater sensitivity and specificity needed 
to do a meta-analysis, could not be confirmed, as the authors did not make their data available 
for this study.  
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 39   
III.2.7. References  
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., . . . Tewari, M. (2011). 
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in 
human plasma. Proceedings of the National Academy of Sciences of the United States of America, 
108(12), 5003-5008. doi:10.1073/pnas.1019055108 
Bisso, A., Faleschini, M., Zampa, F., Capaci, V., De Santa, J., Santarpia, L., . . . Del Sal, G. (2013). Oncogenic 
miR-181a/b afect the DNA damage response in aggressive breast cancer. Cell Cycle, 12(11), 1679-
1687. doi:10.4161/cc.24757 
Cai, Z.-K., Chen, Q., Chen, Y.-B., Gu, M., Zheng, D.-C., Zhou, J., & Wang, Z. (2015). microRNA-155 
promotes the proliferation of prostate cancer cells by targeting annexin 7. Molecular Medicine 
Reports, 11(1), 533-538. doi:10.3892/mmr.2014.2744 
Chen, L., Xu, S., & Li, J. (2011). Recent advances in molecular imprinting technology: current status, 
challenges and highlighted applications. Chemical Society Reviews, 40(5). doi:10.1039/c0cs00084a 
Chu, H., Wei, X., Wu, M., Yan, J., & Tu, Y. (2012). An electrochemiluminescent biosensor based on 
polypyrrole immobilized uricase for ultrasensitive uric acid detection. Sensors and Actuators B-
Chemical, 163(1), 247-252. doi:10.1016/j.snb.2012.01.047 
Chu, H., Yan, J., & Tu, Y. (2011). Electrochemiluminescent detection of the hybridization of oligonucleotides 
using an electrode modified with nanocomposite of carbon nanotubes and gold nanoparticles. 
Microchimica Acta, 175(3-4), 209-216. doi:10.1007/s00604-011-0669-1 
Cui, S.-Y., Wang, R., & Chen, L.-B. (2014). MicroRNA-145: a potent tumour suppressor that regulates 
multiple cellular pathways. Journal of Cellular and Molecular Medicine, 18(10), 1913-1926. 
doi:10.1111/jcmm.12358 
Di Leva, G., & Croce, C. M. (2010). Roles of small RNAs in tumor formation. Trends in Molecular Medicine, 
16(6), 257-267. doi:10.1016/j.molmed.2010.04.001 
Ekin, A., Karatas, O. F., Culha, M., & Ozen, M. (2014). Designing a gold nanoparticle-based nanocarrier for 
microRNA transfection into the prostate and breast cancer cells. Journal of Gene Medicine, 16(11-
12), 331-335. doi:10.1002/jgm.2810 
Fan, Z., Keum, Y. S., Li, Q. X., Shelver, W. L., & Guo, L.-H. (2012). Sensitive immunoassay detection of 
multiple environmental chemicals on protein microarrays using DNA/dye conjugate as a fluorescent 
label. Journal of Environmental Monitoring, 14(5), 1345-1352. doi:10.1039/c2em10956e 
Godfrey, A. C., Xu, Z., Weinberg, C. R., Getts, R. C., Wade, P. A., DeRoo, L. A., . . . Taylor, J. A. (2013). 
Serum microRNA expression as an early marker for breast cancer risk in prospectively collected 
samples from the Sister Study cohort. Breast Cancer Research, 15(3). doi:10.1186/bcr3428 
Guo, L.-J., & Zhang, Q.-Y. (2012). Decreased serum miR-181a is a potential new tool for breast cancer 
screening. International Journal of Molecular Medicine, 30(3), 680-686. 
doi:10.3892/ijmm.2012.1021 
Hao, C., Xua, L., Xing, C., Kuang, H., Wang, L., & Xu, C. (2012). Oligonucleotide-based fluorogenic sensor 
for simultaneous detection of heavy metal ions. Biosensors & Bioelectronics, 36(1), 174-178. 
doi:10.1016/j.bios.2012.04.008 
Hayden, O., Bindeus, R., Haderspock, C., Mann, K. J., Wirl, B., & Dickert, F. L. (2003). Mass-sensitive 
detection of cells, viruses and enzymes with artificial receptors. Sensors and Actuators B-Chemical, 
91(1-3). doi:10.1016/s0925-4005(03)00093-5 
Hayes, E. L., & Lewis-Wambi, J. S. (2015). Mechanisms of endocrine resistance in breast cancer: an overview 
of the proposed roles of noncoding RNA. Breast cancer research : BCR, 17(1), 542-542. 
doi:10.1186/s13058-015-0542-y 
He, L., & Hannon, G. J. (2004). Micrornas: Small RNAs with a big role in gene regulation. Nature Reviews 
Genetics, 5(7), 522-531. doi:10.1038/nrg1379 
Heneghan, H. M., Miller, N., Kelly, R., Newell, J., & Kerin, M. J. (2010). Systemic miRNA-195 Differentiates 
Breast Cancer from Other Malignancies and Is a Potential Biomarker for Detecting Noninvasive and 
Early Stage Disease. Oncologist, 15(7), 673-682. doi:10.1634/theoncologist.2010-0103 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 40   
Huang, H.-M., Huang, P.-K., Kuo, W.-H., Ju, Y.-H., & Wang, M.-J. (2013). Sol-gel immobilized enzymatic 
glucose biosensor on gold interdigitated array (IDA) microelectrode. Journal of Sol-Gel Science and 
Technology, 67(3), 492-500. doi:10.1007/s10971-013-3106-6 
Igglezou, M., Vareli, K., Georgiou, G. K., Sainis, I., & Briasoulis, E. (2014). Kinetics of Circulating Levels of 
miR-195, miR-155 and miR-21 in Patients with Breast Cancer Undergoing Mastectomy. Anticancer 
Research, 34(12), 7443-7447.  
Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., . . . Croce, C. M. (2005). 
MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065-
7070. doi:10.1158/0008-5472.can-05-1783 
Jeffrey, S. S. (2008). Cancer biomarker profiling with microRNAs. Nature Biotechnology, 26(4), 400-401. 
doi:10.1038/nbt0408-400 
Kim, S., Rhee, J.-k., Yoo, H. J., Lee, H. J., Lee, E. J., Lee, J. W., . . . Chang, S. (2015). Bioinformatic and 
metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Letters, 
357(2), 488-497. doi:10.1016/j.canlet.2014.11.058 
Kodahl, A. R., Lyng, M. B., Binder, H., Cold, S., Gravgaard, K., Knoop, A. S., & Ditzel, H. J. (2014). Novel 
circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-
stage breast cancer: A case control study. Molecular Oncology, 8(5), 874-883. 
doi:10.1016/j.molonc.2014.03.002 
Langagergaard, V., Garne, J. P., Vejborg, I., Schwartz, W., Bak, M., Lernevall, A., . . . Mikkelsen, E. M. 
(2013). Existing data sources for clinical epidemiology: the Danish Quality Database of 
Mammography Screening. Clinical epidemiology, 5, 81-88. doi:10.2147/clep.s40484 
Li, M., Marin-Muller, C., Bharadwaj, U., Chow, K.-H., Yao, Q., & Chen, C. (2009). MicroRNAs: Control and 
Loss of Control in Human Physiology and Disease. World Journal of Surgery, 33(4), 667-684. 
doi:10.1007/s00268-008-9836-x 
Liu, J., Mao, Q., Liu, Y., Hao, X., Zhang, S., & Zhang, J. (2013). Analysis of miR-205 and miR-155 expression 
in the blood of breast cancer patients. Chinese Journal of Cancer Research, 25(1), 46-54. 
doi:10.3978/j.issn.1000-9604.2012.11.04 
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., . . . Golub, T. R. (2005). MicroRNA 
expression profiles classify human cancers. Nature, 435(7043), 834-838. doi:10.1038/nature03702 
Lu, Z., Ye, Y., Jiao, D., Qiao, J., Cui, S., & Liu, Z. (2012). miR-155 and miR-31 are differentially expressed 
in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. 
Oncology Letters, 4(5), 1027-1032. doi:10.3892/ol.2012.841 
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by 
microRNA 10b in breast cancer. Nature, 449(7163), 682-U682. doi:10.1038/nature06174 
Martin, E. C., Krebs, A. E., Burks, H. E., Elliott, S., Baddoo, M., Collins-Burow, B. M., . . . Burow, M. E. 
(2014). miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to 
enhanced mitogen activated protein kinase signaling. Genes & cancer, 5(9-10), 353-364.  
Mattiske, S., Suetani, R. J., Neilsen, P. M., & Callen, D. F. (2012). The Oncogenic Role of miR-155 in Breast 
Cancer. Cancer Epidemiology Biomarkers & Prevention, 21(8), 1236-1243. doi:10.1158/1055-
9965.epi-12-0173 
McDermott, A. M., Miller, N., Wall, D., Martyn, L. M., Ball, G., Sweeney, K. J., & Kerin, M. J. (2014). 
Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer. 
Plos One, 9(1). doi:10.1371/journal.pone.0087032 
Michael, M. Z., O'Connor, S. M., Pellekaan, N. G. V., Young, G. P., & James, R. J. (2003). Reduced 
accumulation of specific microRNAs in colorectal neoplasia. Molecular Cancer Research, 1(12), 882-
891.  
Mie, M., Kai, T., Le, T., Cass, A. E. G., & Kobatake, E. (2013). Selection of DNA Aptamers with Affinity for 
Pro-gastrin-Releasing Peptide (proGRP), a Tumor Marker for Small Cell Lung Cancer. Applied 
Biochemistry and Biotechnology, 169(1), 250-255. doi:10.1007/s12010-012-9956-5 
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., . . . Tewari, 
M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 41   
of the National Academy of Sciences of the United States of America, 105(30), 10513-10518. 
doi:10.1073/pnas.0804549105 
Muthiah, M., Islam, M. A., Lee, H.-J., Moon, M.-J., Cho, C.-S., & Park, I.-K. (2015). MicroRNA delivery with 
osmotic polysorbitol-based transporter suppresses breast cancer cell proliferation. International 
journal of biological macromolecules, 72, 1237-1243. doi:10.1016/j.ijbiomac.2014.10.041 
Ng, E. K. O., Li, R., Shin, V. Y., Jin, H. C., Leung, C. P. H., Ma, E. S. K., . . . Kwong, A. (2013). Circulating 
microRNAs as Specific Biomarkers for Breast Cancer Detection. Plos One, 8(1). 
doi:10.1371/journal.pone.0053141 
Roth, C., Rack, B., Mueller, V., Janni, W., Pantel, K., & Schwarzenbach, H. (2010). Circulating microRNAs 
as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer 
Research, 12(6). doi:10.1186/bcr2766 
Rupcich, N., Nutiu, R., Li, Y. F., & Brennan, J. D. (2005). Entrapment of fluorescent signaling DNA aptamers 
in sol-gel-derived silica. Analytical Chemistry, 77(14), 4300-4307. doi:10.1021/ac0506480 
Ryan, B. M., Robles, A. I., & Harris, C. C. (2010). Genetic variation in microRNA networks: the implications 
for cancer research (vol 10, pg 389, 2010). Nature Reviews Cancer, 10(7). doi:10.1038/nrc2885 
Sachdeva, M., & Mo, Y.-Y. (2010). MicroRNA-145 Suppresses Cell Invasion and Metastasis by Directly 
Targeting Mucin 1. Cancer Research, 70(1), 378-387. doi:10.1158/0008-5472.can-09-2021 
Sharma, P. S., Pietrzyk-Le, A., D'Souza, F., & Kutner, W. (2012). Electrochemically synthesized polymers in 
molecular imprinting for chemical sensing. Analytical and Bioanalytical Chemistry, 402(10), 3177-
3204. doi:10.1007/s00216-011-5696-6 
Singh, R., & Mo, Y.-Y. (2013). Role of microRNAs in breast cancer. Cancer Biology & Therapy, 14(3), 201-
212. doi:10.4161/cbt.23296 
Sun, E. H., Zhou, Q., Liu, K. S., Wei, W., Wang, C. M., Liu, X. F., . . . Ma, D. Y. (2014). Screening miRNAs 
related to different subtypes of breast cancer with miRNAs microarray. European review for medical 
and pharmacological sciences, 18(19), 2783-2788.  
Sun, X., Du, S., Wang, X., & Qi, B. (2012). A Novel Label-Free Impedance Immunosensor Based on Sol-Gel 
for Determination of Carbofuran. Sensor Letters, 10(1-2), 330-334. doi:10.1166/sl.2012.1848 
Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., & Li, J. (2012). Serum MicroRNA-155 as a Potential 
Biomarker to Track Disease in Breast Cancer. Plos One, 7(10). doi:10.1371/journal.pone.0047003 
Taplin, S., Abraham, L., Barlow, W. E., Fenton, J. J., Berns, E. A., Carney, P. A., . . . Elmore, J. G. (2008). 
Mammography facility characteristics associated with interpretive accuracy of screening 
mammography. Journal of the National Cancer Institute, 100(12), 876-887. doi:10.1093/jnci/djn172 
Taylor, M. A., Sossey-Alaoui, K., Thompson, C. L., Danielpour, D., & Schiemann, W. P. (2013). TGF-beta 
upregulates miR-181a expression to promote breast cancer metastasis. Journal of Clinical 
Investigation, 123(1), 150-163. doi:10.1172/jci64946 
Tsang JY, N. Y., Ng EK, Shin VY, Mak KF, Go EM, Tawasil J, Chan SK, Ko CW, Kwong A, Tse GM. (2015). 
MicroRNAs are differentially deregulated in mammary malignant phyllodes tumour. Histopathology. 
doi:10.1111/his.12648 
Turner, N. W., Jeans, C. W., Brain, K. R., Allender, C. J., Hlady, V., & Britt, D. W. (2006). From 3D to 2D: 
A review of the molecular imprinting of proteins. Biotechnology Progress, 22(6). 
doi:10.1021/bp060122g 
van Schooneveld, E., Wouters, M. C. A., Van der Auwera, I., Peeters, D. J., Wildiers, H., Van Dam, P. A., . . 
. Van Laere, S. J. (2012). Expression profiling of cancerous and normal breast tissues identifies 
microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer 
and healthy volunteers. Breast Cancer Research, 14(1). doi:10.1186/bcr3127 
Wang, J., Rivas, G., Fernandes, J. R., Jiang, M., Paz, J. L. L., Waymire, R., . . . Getts, R. C. (1998). Adsorption 
and detection of DNA dendrimers at carbon electrodes. Electroanalysis, 10(8), 553-556. 
doi:10.1002/(sici)1521-4109(199807)10:8<553::aid-elan553>3.0.co;2-7 
Wang, P.-Y., Gong, H.-T., Li, B.-F., Lv, C.-L., Wang, H.-T., Zhou, H.-H., . . . Jiang, B.-F. (2013). Higher 
expression of circulating miR-182 as a novel biomarker for breast cancer. Oncology Letters, 6(6), 
1681-1686. doi:10.3892/ol.2013.1593 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 42   
Whitcombe, M. J., Chianella, I., Larcombe, L., Piletsky, S. A., Noble, J., Porter, R., & Horgan, A. (2011). The 
rational development of molecularly imprinted polymer-based sensors for protein detection. Chemical 
Society Reviews, 40(3). doi:10.1039/c0cs00049c 
Wijnhoven, B. P. L., Michael, M. Z., & Watson, D. I. (2007). MicroRNAs and cancer. British Journal of 
Surgery, 94(1), 23-30. doi:10.1002/bjs.5673 
Wu, X., Zeng, R., Wu, S., Zhong, J., Yang, L., & Xu, J. (2015). Comprehensive expression analysis of miRNA 
in breast cancer at the miRNA and isomiR levels. Gene, 557(2), 195-200. 
doi:10.1016/j.gene.2014.12.030 
Yu, D.-D., Lv, M.-M., Chen, W.-X., Zhong, S.-L., Zhang, X.-H., Chen, L., . . . Zhao, J.-H. (2015). Role of 
miR-155 in drug resistance of breast cancer. Tumour biology : the journal of the International Society 
for Oncodevelopmental Biology and Medicine, 36(3), 1395-1401. doi:10.1007/s13277-015-3263-z 
Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007). microRNAs as oncogenes and tumor suppressors. 
Developmental Biology, 302(1), 1-12. doi:10.1016/j.ydbio.2006.08.028 
 
  
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 43   
III.3.  A novel and simple approach for monitoring attomolar 
concentrations of miRNA-155 in Breast Cancer 
Ana R. Cardosoa,b, Felismina T.C. Moreiraa, Rúben Fernandesb,c, M. Goreti F. Salesa* 
 
aBioMark-CINTESIS/ISEP, School of Engineering, Polytechnic Institute of Porto, Portugal 
bMolecular Mechanisms of Disease Unit, Centre of Research in Health and Environment (CISA), ESTSP-
IPP; 
cMetabolism, Nutrition and Endocrinology Unit, Integrative Cancer Programe, Instituto de Investigação 
e Inovação em Saúde (i3S), University of Porto. 
 
 
 
 
 
 
 
To whom correspondence should be addressed: Goreti Sales, BioMark-Cintesis/ISEP, 
Instituto Superior de Engenharia do Porto, R. Dr. António Bernardino de Almeida, 341, 
4200-072 Porto, Portugal; Tel.: +351 228 340 544; Fax: +351 228 321 159; Email: 
goreti.sales@gmail.com; mgf@isep.ipp.pt.  
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 44   
III.3.1. Abstract 
This work, describes for the first time, a simple biosensing design to yield an ultrasensitive 
electrochemical biosensor for a cancer biomarker detection, miRNA-155, with linear 
response down to the attomolar range. MiRNA-155 was selected for being overexpressed in 
breast cancer. 
The biosensor was assembled in two stages: (1) the immobilization of the anti-miRNA-155 
that was thiol modified on an Au-screen printed electrode (Au-SPE), followed by (2) 
blocking the areas of non-specific binding with mercaptosuccinic acid. The hybridization 
between anti-miRNA-155 and miRNA-155 yielded changes in the electrical properties of 
the biosensor. Atomic force microscopy (AFM) and electrochemical techniques including 
cyclic voltammetry (CV), impedance spectroscopy (EIS) and square wave voltammetry 
(SWV) confirmed the surface modification of these devices and their ability to hybridize 
successfully and stably with miRNA-155.  
The final biosensor provided a sensitive detection of miRNA-155 from 10.0 aM to 1nM with 
a low detection limit (LOD) of 5.7 aM in real human serum samples. Good results were 
obtained in terms of selectivity towards breast cancer antigen CA-15.3 and bovine serum 
albumin (BSA) proteins, which are commonly present in human serum from breast cancer 
patients in relatively high amounts. Raw fluid extracts from cell-lines of melanoma did not 
affect the biosensor response (no significant change of the blank), while raw extracts from 
breast cancer yielded a positive signal against miRNA-155, as expected. 
This simple and sensitive strategy is a promising alternative for simultaneous quantitative 
analysis of multiple miRNA in physiological fluids for biomedical research and point-of-
care (POC) diagnosis. 
 
Keywords: Breast cancer; Anti-miRNA-155; miRNA-155; Biosensors, Eletrochemistry. 
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III.3.2. Introduction  
Cancer is a public health concern worldwide. One in three women and one in two men will 
develop cancer during lifetime in developed countries (Siegel et al., 2012). Early detection 
is the only known approach that may improve these indicators, but traditional diagnostic 
tools for breast cancer detection are mostly ineffective, including: i) clinical and physical 
examinations, ii) imaging mammography, iv) ultrasound magnetic resonance imaging and 
v) histopathology. Clinical and physical examination have been shown insufficient, driving 
patients into mammography or ultrasound studies. In turn, mammography has limited 
sensitivity, yielding a high rate of false positive results. This approach may also lead to an 
accumulated exposure to radiation, which is considered an additional and significant risk 
factor (Yahalom et al., 2013). Ultrasound is a non-invasive and safe tool, but it cannot 
replace mammograms, especially in women above 40, and is unable to screen many of the 
cancers. Thus, there is urgent need to develop non-invasive, simple and low risk methods 
for screening/diagnosing breast cancer. Considering the high prevalence of cancer diseases 
and the high frequency of analysis to be performed in clinical context, there is a strong need 
that such test are made available in POC point-of-care (POC) (Riaz et al., 2013). (Grieshaber 
et al., 2008). 
Currently, strong efforts are being developed to monitor serum biomarkers as early detection 
of cancer. The measurement of a panel of such biomarkers is considered an economic and 
minimally invasive diagnostic assay, able to provide safe information about the presence or 
absence of the disease, as well as its joint evolution to other clinical and pathological 
approaches (Mirabelli & Incoronato, 2013) (Chung et al., 2014). 
In breast cancer, the most prevalent serum markers used in clinical practice are 
carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA 15-3), circulating 
cytokeratins such as tissue polypeptide antigen (TPA), tissue polypeptide specific antigen 
(TPS) and cytokeratin 19 fragment (CIFRA-21-1), and the proteolytically cleaved 
ectodomain of the human epidermal growth factor receptor 2 (s-HER2). The most widely 
used serum biomarker is CA 15-3, however, due to its lack of sensitivity at an early stage of 
the disease, it cannot be used exclusively. In addition, this marker can lead to false results 
after initiation of treatment without clinical correlation. Also, other biomarkers like TPA and 
CEA are less sensitive than CA-15.3 (Sun et al., 2012). 
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But recent technological advances have led to the identification of a new class of biomarkers 
named miRNAs that may lead to a novel strategy in early cancer screening (He et al., 2015; 
Volinia et al., 2012). MiRNAs contain 18-24 nucleotides in length (Johnson & Mutharasan, 
2014) and play an essential role in biological processes such as development, cellular 
proliferation, apoptosis and response to stress, and tumorigenesis. Aberrant expression levels 
of miRNAs have been observed in many solid tumours, including breast cancer (Fu et al., 
2011), accounting their dysregulated expression in cancer. In addition, miRNAs are stable 
in the blood and have high/low expressions that can be correlated to chemo-resistance, 
(Kong et al., 2010) (Tavallaie et al., 2015). 
In breast cancer, several studies have supported an abnormal expression of miRNA-155 
(MIR-155) in patients with the disease (Mattiske et al., 2012). The overexpression of MIR-
155 was considered as a breast cancer risk factor (Zeng et al., 2014), being associated with 
clinical-pathological markers, tumour subtype, poor survival rates, metastasis events and 
invasive properties of breast cancer, as well as high tumour grade, advanced stage and lymph 
node metastasis (Mattiske et al., 2012). MIR-155 is involved in controlling several 
mechanisms of cell survival, cell growth, radio/chemo-resistance (Liu et al., 2015) (Mattiske 
et al., 2012) (Liu et al., 2015), inhibiting target genes such as FOXO3A, RhoA, and SOCS1. 
The use of miRNA-155 as a potential biomarker in breast cancer opens the possibility 
towards a simple serological test for prognosis/diagnosis and follow-up of breast cancer 
under therapy.  
Biosensors are today a successful route towards POC testing, allowing fast results and a 
direct sample reading, without the need for transporting samples into the laboratory 
(Campuzano et al., 2014) (Labib and Berezovski, 2015) (Bohunicky and Mousa, 2011). 
Devices relying in electrochemical transduction are currently the most common type of 
biosensors. This is an outcome of their portability, simplicity, sensitivity, low cost, small 
size, rapidity of response, ease of use, and possibility of reading samples directly over a wide 
range of concentrations (Xia and Zhang, 2014). In general, these features of electrochemical 
biosensors depend of the recognition element immobilized on the transducer, which is 
responsible for interacting with the analyte in a selective mode (Choi et al., 2010) 
(Grieshaber et al., 2008).  
In electrochemical miRNA detection, the recognition elements are mostly linear 
oligonucleotide strands of DNA/RNA nature with which the miRNA target hybridizes 
(Catuogno et al., 2011; Johnson & Mutharasan, 2014; Tavallaie, De Almeida, & Gooding, 
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2015). The transduction event measures the changes in the electrode or interfacial properties 
occurring upon hybridization, by means of electrochemically-active reporter species, 
including small redox molecules (such as ferric species, guanine oxidation) or enzyme-
substrate pairs (such as horseradish peroxidase/hydrogen peroxide) (Johnson & Mutharasan, 
2014). Concurrent methods are mostly devoted to biosensors using other transduction modes 
(optical or electromechanical) or molecular-based approaches, including polymerase 
amplification, microarray (coupled to amplification approaches), spectroscopy, sequencing, 
cloning, and Northern blotting (Johnson & Mutharasan, 2014). Biosensors with other modes 
of transduction are typically linked to higher detection levels and molecular based 
approaches involve complex operations that are either expensive or far from POC 
requirements. 
Regarding the specific electrochemical determination of miRNA-155, there is a limited 
number of works reported in the literature. The first one was presented by (X. Wu, Chai, 
Yuan, Su, & Han, 2013), combining a conductive composition of Nafion, thionine (Thi) and 
Pd nanoparticles, displaying electrocatalytic activity for H2O2, and providing an LOD of 
~1.9 pM.  Zhu et al., 2014, combined high base-mismatch selectivity of ligase chain reaction 
with reporting probes labeled with two different quantum dots (Zhu, Su, Gao, Dai, & Zou, 
2014). This elegant and complex approach had an LOD of 12-31 fM. Later on, Wu et al. 
2015 presented another biosensor based on catalyzed hairpin assembly target recycling and 
cascade enzymatic electrocatalysis for signal amplification, in a quite complex approach, to 
yield an LOD of 0.35 fM  (S. Wu et al., 2015). Hu et al., 2015 presented an horseradish 
peroxidase and graphene quantum dots combination, this time giving rise to a 0.14 fM LOD 
(Hu, Zhang, Wen, Zhang, & Wang, 2015). Very recently, Azimzadeh et al. 2015, has 
proposed the modification of glassy carbon electrode surface by a thiolated probe-
functionalized with gold nanorods and decorated on the graphene oxide material, having as 
reporter label Oracet Blue. The LOD was higher than the previously reported, equal to 0.6 
fM (Azimzadeh, Rahaie, Nasirizadeh, Ashtari, & Naderi-Manesh, 2015). Overall, the 
previous attempts of producing a sensitive device for miRNA detection have been effective 
but quite complex in terms of biosensor assembly and no significant improvements in terms 
of analytical features have been gained within time.  
Thus, a simple and low cost concurrent approach would be appreciated, especially if a direct 
reading of serum samples is rendered possible and if the biosensor assembly is set to a 
minimum complexity, trying to carefully optimize critical variables, instead. Thus, the main 
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goal of this work is the development of an alternative approach that may lead to a sensitive 
and selective electrochemical biosensing of miRNA-155 in breast cancer, and yielding better 
analytical features than those reported so far. The biorecognition element used herein is the 
complementary oligonucleotide of synthetic origin (anti-miRNA-155) that was simply 
immobilized on Au Screen printed electrodes (Au-SPE). Non-specific binding was blocked 
with mercaptosuccinic acid modification, for subsequent hybridization of the anti-MIR with 
the target analyte, MIR-155. All studies regarding the chemical modification and 
optimization of the biosensor design, electrical characterization, and analytical application 
are presented herein. 
 
III.3.3. Experimental section  
III.3.3.1. Apparatus  
The electrochemical measurements were performed with a potentiostat/galvanostat from 
Metrohm Autolab, PGSTAT320N, controlled by NOVA 1.11 software. The gold-screen 
printed electrodes (Au-SPEs) were purchased from DropSens (DS-C220AT), built with (i) 
a counter electrode made of gold; (ii) a reference electrode and electrical contacts made of 
silver; and (iii) a gold working electrode with 4 mm diameter. Also, the Au-SPEs were 
interfaced in switch box from DropSens, allowing reading electrochemical assays. 
UV/Vis studies were made in the spectrophotometer Evolution 220 UV-visible from Thermo 
Scientific. AFM studies were made in a Nanoscope IVA from Veeco Metrology Multimode. 
 
III.3.3.2. Reagents  
The water used in this work was ultrapure Mili-Q laboratory grade (conductivity 
˂0.1µS/cm). In specific assays, the water was autoclaved with 0.1% diethylpyrocarbonate 
(DEPC) in order to increase the MIR stability by decreasing RNase activity.  
The chemical reagents used along this work were used without further purification. 
Potassium hexacyanoferrate III (K3[Fe(CN)6]), potassium hexacyanoferrate II 
(K4[Fe(CN)6]) trihydrate, magnesium chloride (MgCl), and sodium phosphate (Na2HPO4), 
all obtained from Riedel-deHaen; Serum cornay human was purchased from PZ CORMAY 
S.A., Poland; Phosphate buffer saline (PBS) and bovine serum albumin (BSA) were from 
Amresco; Calcium chloride (CaCl) and potassium chloride (KCl) from Merck; 
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Ethylenediamine tetraacetic acid (EDTA) from BDH; Sodium chloride (NaCl) and absolute 
ethanol (99.5%) from Panreac; Hydroxymethyl-aminomethane (Tris) from Fisher 
BioReagents; Sodium citrate (Na3C6H5O7) from Analar Normapur; Sulphuric acid (H2SO4), 
dithiothreitol (DTT), mercaptosuccinic acid (MSA, 97%), DEPC, and cancer antigen 15-3 
(CA-15.3) from Sigma. 
The oligonucleotide probes were Anti-miRNA-155 (oligonucleotide) and miRNA-155, 
purified by HPLC and obtained from the Metabion. The sequences are as follows: anti-
miRNA-155 (anti-miRNA155), 5’-HS-AAA AAA AAC CCC UAU CAC GAU UAG CAU 
UAA-3’; miRNA-155 (miRNA-155), 5’-UUA AUG CUA AUC GUG AUA GGG GU-3’. 
 
III.3.3.3. Solutions 
All solutions were prepared in ultrapure water, autoclaved with 0.1% DEPC. The stock 
solution of oligonucleotide (1.16 µg/ml, Anti-miRNA) was prepared in SSPE buffer 
containing 0.02 M EDTA, 2.98 M NaCl and 0.2 M phosphate buffer (20× diluted, pH 7.4).  
The stock solution of 0.6 µg/mL of miRNA-155 was prepared in Tris-HCl, containing 0.02 
M Tris, 0.14 M NaCl, 0.001 M MgCl2, 0.005 M KCl and 0.001 M CaCl2 (pH 7.4). Less 
concentrated standards were obtained by accurate dilution of the previous solution in 0.01 
M Tris buffer containing 0.001 M EDTA and 0.05 M NaCl (pH 7.4). The immobilization 
and hybridization buffer were prepared in the some buffer solution. The buffer for 
regeneration (SSC) contained 3.0 M NaCl and 0.3 M trisodium citrate (0.1× diluted, pH 7.4). 
Solutions of interfering species were prepared in the same buffer used in the immobilization 
and hybridization stages. The concentration of miRNA-155 was 0.6 µg/ml and the 
interfering species were BSA (0.30µg/ml) and CA-15.3 (30U/mL). The miRNA-155 
solutions were prepared in real human serum (Cornay Human Serum), 1000× diluted. The 
electrochemical studies were made in a solution of 5.0×10-3 M of K3[Fe(CN)6] and 5.0×10
-
3 M of K4[Fe(CN)6] redox probe, prepared in PBS buffer, pH 7.4. 
 
III.3.3.4. Preparation of electrochemical biosensor on Au-SPE 
Before modification, the working Au-SPE surface was cleaned by washing with absolute 
ethanol, followed by CV electrochemical treatment with 0.5 M H2SO4, for 10 cycles (500 
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mV/s; -0.1 to 1.5V). Finally, the Au surface was washed with ultrapure water in order to 
eliminate chemical compounds.  
The synthesis of the biosensor was made in two steps. Step (1) consisted in incubating anti-
miRNA155 (1µM/mL) with DTT (0.1M) on the Au-SPE working area. The probe solution 
was prepared in buffer, pH 7.4 that contained Tris, EDTA, NaCl, previously heated at 90ºC 
for 5 minutes, and incubated for 2h at room temperature. The electrode surface was then 
washed with ultrapure water several times. In step (2) the non-specific binding areas were 
blocked by incubation the sensory surface with 0.002 µg/mL MSA, for 2h, at room 
temperature. The hybridization of the probe with the target miRNA-155 was made with 
several miRNA-155 standards solutions, prepared in buffer or in blank sera. Each standard 
was incubated for 30 minutes at 37ºC. 
 
III.3.3.5. UV Characterization 
The hybridization stage occurring between probe and target miRNA was followed out of the 
biosensor format by UV-Vis spectrophotometry. It was done by measuring the spectral data 
of each individual solution (Anti-miRNA155, miRNA-155; and mixture of both) in the 
spectral range from 220 to 300 nm. 
 
III.3.3.6. AFM analysis 
The morphological analysis of biosensor was performed by AFM in tapping mode. All 
surface characterization studies were conducted on planar Au surfaces employed in regular 
surface plasmon resonance (SPR) measurements. For this, anti-miRNA-155, Anti-miRNA-
155/ MSA and anti-miRNA-155/MCA/miRNA155 materials were assembled on SPR planar 
gold chips following the same procedure as that described for the Au-SPEs. The analysis of 
AFM images were collected and handled by the nanoscope software, coupled to the same 
equipment. 
III.3.3.7. Electrochemical Procedures 
All electrochemical assays were conducted in triplicate. CV assays was made for scanning 
potentials from -0.5 to +0.5 V, at a scan-rate of 50 mV/s. EIS assays were performed at an 
open circuit potential, using a sinusoidal potential perturbation with an amplitude of 0.01V, 
and 50 data points, logarithmically distributed over 0.1 to 100000 Hz frequency range. The 
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EIS data was fitted into a Randles equivalent circuit using 1.11 Nova Software from Autolab. 
SWV assays were conducted for a potential range from -0.2 to +0.8 V, with a frequency of 
25 Hz and a step height of 50mV.  
The electrical properties of modified surfaces were followed-up by CV, EIS and SWV 
assays, performed in a redox probe solution of 5.0×10-3 M of [Fe(CN)6]
3- and 5.0×10-3 M of 
[Fe(CN)6]
4-, prepared in PBS buffer, pH 7.4. Calibration curves made use of EIS and SWV 
assays and included standard solutions of miRNA-155, prepared in Tris buffer pH 7.4 
(ranging from 1.0 fM to 10 nM), or in human serum (ranging from 0.01 aM to 10 nM). The 
LOD was calculated as X+3σ, where X was the average value of EIS or SWV for blank 
signals (obtained in the absence of miRNA-155) and σ is the known standard deviation of 
EIS or SWV for the blank’s signal (Harvey, 2000). 
Selectivity studies were conducted by competitive assay between miRNA-155 with two 
different biomolecules that can be found in biological fluids, such as BSA (0.30 µg/mL) and 
CA-15.3 (30 U/mL).  
 
III.3.3.8. MiRNA-155 assay  
The performance of the biosensor was analysed by the standard addition method, in order to 
determine the miRNA-155 concentration in spiked human blank serum. MiRNA-155 
concentrations were set to different levels, equal to 0.1 pM and 100 pM, always lying within 
the linear range of the device. The human serum was diluted in TRIS buffer. All the assays 
were conducted in duplicate and analytical data was collected in EIS. 
 
III.3.4. Results and Discussion  
III.3.4.1. Biosensor assembly  
The schematic construction of the miRNA-155 biosensor is shown in Figure 1, and involved 
three main stages: (1) Au-SPE pre-treatment; (2) oligonucleotide immobilization and (3) 
non-specific binding blockage. The miRNA-155 hybridization assay was the final approach 
made with the biosensor, and concerned the analytical stage.  
Initially, Au-SPEs were cleaned first by washing with ethanol, two times, and after by 
electrochemical cleaning, making use of consecutive CV assays in a H2SO4 solution. This 
oxidative stage allowed the oxidation of any organic species allocated on the surface and 
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improved the electrochemical properties of the bare Au electrode, by decreasing the peak-
to-peak separation of the Fe redox probe and increasing peak currents. 
The probe was then covalently bond to the clean SPE by incubating the Au working electrode 
in a solution of anti-miRNA-155 with a thiol group at its 5’end, in a hydrated chamber, at 
room temperature, and for a set time period. (Figure 6A). The probe had several consecutive 
adenine nucleotides between the –SH end and the complementary sequence to miRNA-155, 
acting as spacer and conferring mobility to the probe (in order to reduce steric hindrance at 
the hybridization stage). Before incubation, the anti-miRNA-155 probe was treated with 
0.10M DTT for 15 minutes, in order to disrupt disulphide bonds, and warmed at 90ºC for 5 
minutes to ensure that the strand had a linear pattern. This last heating stage was found 
crucial, as without it the amount of immobilized probe was much smaller (less than 10%) 
and irreproducible. 
Next, the non-specific binding was blocked with MSA (Figure 6B). This compound has an 
–SH bond allowing its covalent binding to free Au areas existing on the working electrode. 
This stage was fundamental to avoid the direct interaction between any biomolecule in a 
sample and the gold. 
The analytical event involved the hybridization between the probe and miRNA-155. It was 
made by incubating the working electrode area with different concentrations of target 
miRNA (Figure 6C). The different standard solutions were incubated on the working Au-
SPE surface at 37ºC, for a set amount of time.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Schematic illustration of electrochemical biosensor for detection of miRNA-155. (A) 
Immobilization of Anti-miRNA-155 on gold surface; (B) Blocking the non-specific binding; and (C) 
Hybridization with miRNA-155. 
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III.3.4.2. Morphological characterization of the biosensor 
The morphological features resulting from each modification stage were studied on planar 
gold surfaces, previously employed in regular SPR measurements and cleaned by oxidative 
solution. This was a fundamental strategy, as the Au layer on the SPEs was deposited by 
printing approaches and therefore its surface was too rough to allow detecting any 
morphological change promoted by a single monolayer modification.  
Thus, the study was made on three different assemblies: clean Au-SPR, Au-SPR/Anti-
miRNA155 and Au-SPR/Anti-miRNA-155/miRNA-155 (Figure 7), prepared as described 
for the SPEs. The first image shows the typical observation of the clean gold surface (Figure 
7A). This surface was not as flat as expected, because the Au-SPR had been reused in 
previous experiments. Still, its roughness was low enough to allow detecting changes related 
to the subsequent chemical modification.  
Indeed, the immobilization of the Anti-miRNA-155 on the clean Au-SPE rendered 
significant changes (Figure 7B), both in surface roughness (2.84 nm) and deepness (127.50 
nm). The observed surface showed more roughness and deepness compared with the clean 
gold (1.39 nm and 17.57 nm, respectively), which was consistent with the addition of a 
miRNA monolayer onto the Au-SPE surface.  
Finally, the miRNA-155 hybridization on the Au-SPR/Anti-miRNA155 surface produced 
greater morphological changes (Figure 7C). Both roughness and deepness decreased due to 
the hybridization event, thereby confirming that the complementary oligonucleotide 
sequences hybridized. The formation of an apparently more flat surface could be justified by 
the presence of stable double strand oligonucleotide formations of negative charge, 
distributed all around the surface and all of the same length; the strong negative outer surface 
in each double strand formation would contribute to repel each other and create an image of 
a homogenous surface.  
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Figure 7: AFM images in 2D (below) and 3D (on top) views of different materials. (A) Au-SPR (B) Au-
SPR/Anti-miRNA155 and (C) Au-SPR/Anti-miRNA-155/miRNA-155. 
 
III.3.4.3. UV Characterization  
After making the morphological characterization of the surface, UV/Vis absorption 
spectroscopy was carried out, in order to confirm that the reaction between Anti-miRNA-
155 and miRNA-155 had occurred. This was done because, according to the literature, 
nucleic acids, nucleosides, and nucleotides absorb strongly UV light, and the sum of their 
individual nitrogenous bases generates the overall absorbance in the UV spectrum of DNA 
and RNA (RNA Nanotechnology, 2014). The results obtained are shown in Figure 8. 
The UV spectra of individual solutions of anti-miRNA-155 and mirRNA155 had a single 
peak, around ~290 nm (Figure 8A and B). This confirmed the existence of oligonucleotide 
species in single-strand formation. According to literature, the molecules responsible for the 
absorbance of radiation at this wavelength are the aromatics nitrogenous bases (adenine and 
uracil; cytosine and guanine) (RNA Nanotechnology, 2014).  
After mixing both solutions (Figure 8C), the spectra showed no peaks. During this stage, 
hybridization led to nitrogenous base pairing, resulting in the absence of absorbance by the 
solution. This lack of the absorption upon hybridization was led by a hypsochromic shift, as 
stacking of nitrogenous bases in native miRNA-155 interfered with UV absorption. Thus, 
these results have proven that the hybridization process had successfully occurred between 
anti-miRNA-155 and miRNA-155 single strands in the test solution.  
Au-SPR Au-SPR/Anti-miRNA-155 Au-SPR/Anti-miRNA-155/miRNA-155
A B C
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Moreover, when the hybridized strands were separated by heat, the peak of absorbance of 
light was recovered. This phenomenon corresponded to subsequent bathochromic shift (RNA 
Nanotechnology, 2014) and confirmed the possibility of reversing the hybridization stage.  
  
Figure 8: UV/Vis absorption spectroscopy of the Anti-miRNA-155 (A) and miRNA-155 (B) and respective 
complex.  
 
III.3.4.4. Electrochemical control of the gold surface modifications 
The chemical modification of the Au-SPE surface produced alterations in its electrical 
features, evaluated by monitoring the electron transfer properties of a standard redox system. 
Different redox systems were tested for this purpose (Ruthenium and Iron), prepared in 
different buffer conditions. A redox probe of [Fe(CN)6]
4-/[Fe(CN)6]
3- was selected, at pH 
7.4, as the electrical changes monitored by these conditions generated more sensitive 
alterations at the detected signal. The electrochemical approaches used for this purpose were 
CV, EIS and SWV assays. 
CV analysis is shown in Figure 9A. When compared to the clean surface, the Au-SPE 
modified with anti-miRNA and MSA showed increased peak-to-peak potential separation 
and decreased cathodic/anodic peak currents. This accounted an increased charge-transfer 
resistance at the Au-SPE surface after each modification stage. After hybridization with 
miRNA-155 (Au-SPE/Anti-miRNA-155/miRNA-155), the peak current decreased more, 
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and a slight shift was observed in the peak potentials, thereby confirming the occurrence of 
chemical changes.  
 
Figure 9: Electrochemical assays for controlling the gold surface modification, in 5.0×10-3 M [Fe(CN)6 ]3- and 
5.0×10-3 M [Fe(CN)6]4-, solution, prepared in in buffer (TRIS with EDTA and NaCl). CV (A), EIS (B) and 
SWV (C) assays. 
 
The corresponding EIS measurements are shown in Figure 10 and were consistent with CV 
data. Randle’s equivalent circuit was used to fit the physico-chemical process occurring at 
the gold electrode surface and EIS spectra were represented as Nyquist plots – including a 
semicircle, in which the diameter corresponded to the electron transfer resistance (Rct) 
(Panagopoulou, Stergiou, Roussis, & Prodromidis, 2010) and the linear part represented the 
diffusion limited process (Suni, 2008). The Randle’s equivalent circuit included several 
elements, in which the high frequency region is dominated by the double layer capacitance 
(Cdl) and the magnitude of the electrolyte solution resistance (Rs) (X. Liu, Duckworth, & 
Wong, 2010); the charge-transfer resistance (Rct), which is inversely proportional to the rate 
of electron transfer; and the Warburg diffusion element (W) at higher frequencies, 
accounting for the diffusion of ions. Overall, the bare gold electrode showed a straight line 
or very small semicircle domain, which suggested a mass diffusion limiting step of the 
electron transfer process. After, the immobilization of thiol-based materials on the clean Au-
SPE, the diameter of the semicircle of the Nyquist plot increased considerably. This 
observation was consistent with an increased electron transfer resistance at the surface, 
enhanced by the fact that the single strand anti-miRNA155 was negatively charged through 
its phosphate backbone, thereby hampering the electrode transfer event of a negatively 
charged redox couple (S. Wu et al., 2015). The hybridization of the probe with miRNA-155 
also increased the Rct values, thereby confirming its effect upon the electron transfer and the 
increased density of negative charges occurring at the surface. 
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SWV data is presented in Figure 9C and is also consistent with EIS and CV assays. As it is 
more sensitive than CV, the changes in electrical transfer properties of the several 
modification stages were more evident in SWV. Voltammograms indicated a decrease in 
peak current for assembly and hybridization events. 
Overall, CV, EIS and SWV assays were consistent, and confirmed the occurrence of 
chemical changes at the gold surface, both at the biosensor assembly and at the hybridization 
event. From a practical point of view, EIS and SWV techniques seemed more sensitive to 
the hybridization event, being therefore selected for the subsequent analytical application.  
III.3.4.5. Analytical Performance of miRNA sensor  
The analytical performance of the biosensor was evaluated by calibration curves in EIS and 
SVW measurements. For this, increasing concentrations of miRNA-155 were incubated at 
the surface for a specific amount of time, and the resulting Rct (in EIS) or current intensity 
(I, in SWV) values obtained with the iron redox probe measured against logarithm of 
miRNA-155 concentration. It is important to highlight that several variables were evaluated 
and optimized, including concentration, temperature and time given for the incubation of 
anti-miRNA solution on the clean gold surface, time and temperature given for the 
hybridization stage, buffer composition, etc.. The analytical data presented next regards only 
the best conditions selected. 
In general, EIS (Figure 10A) measurements showed that increasing concentrations of 
miRNA-155 increased the electrical resistance of the surface, as the diameter of the 
semicircles in the Nyquist plots increased. A linear plot was observed between logarithm 
Rct and logarithm of miRNA-155 concentration. The response of the biosensor in EIS was 
tested in three calibrations, made with independent sensors, in different days, and was found 
highly reproducible. All these showed a linear trend between 1.0 fM and 100 pM.  As may 
be seen in Figure 10B, the second and third calibrations had an average slope of 0.086 
logΩ/decade, with a standard of deviation 2.2 %. The squared correlation coefficient of all 
calibrations was always >0.99, and the average limit of detection was 0.54 fM.  
SWV assays also showed linear plots, but this time between current intensity (I, in SWV) 
and logarithm of miRNA-155 concentration. The linear behaviour was observed from 1.0 
fM and 10 nM (Figure 10C). The increasing miRNA-155 concentrations were revealed by 
the decreasing peak currents of redox probe solution. The following calibrations are 
presented in Figure 3D, showing average slopes of 25.18 µA/decade and square correlation 
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coefficients >0.99. The standard of deviation of the these assays was ~0,5% (Figure 3D), 
and the limit of detection was 2.8 aM.  
Overall, the assembled biosensor showed consistent, sensitive and reproducible calibration 
curves, both EIS and SWV assays. The obtained results suggested that the biosensor 
displayed a highly selective and sensitive response against miRAN-155.  
  
Figure 10: EIS(A) and SWV(C) measurements, and the corresponding calibration curves (B e D), in 5.0×10-3 
M [Fe(CN)6]3- and 5.0×10-3 M [Fe(CN)6]4-, in buffer (TRIS with EDTA and NaCl), pH 7.4, with different 
concentration of miRNA-155.  
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III.3.4.6. Regeneration of Au-SPE 
The regeneration of a biosensor after a calibration assay maybe achieved by several physical 
(enthalpic interaction, entropic interactions, thermal regeneration-temperature) and chemical 
(acid/base-mediated regeneration, detergents, glycine, urea and another buffers) approaches. 
In this work, physical (temperature) and chemical (buffer treatment) assays were tried out 
(Goode, Rushworth, & Millner, 2014) and the results presented in Figure 11. 
The temperature was considered as an important parameter to be tested herein since the 3D 
structure of oligonucleotides is typically affected by temperature changes. A temperature 
increase leads to increased kinetic energy of the molecules, which allows binding forces to 
be overcome after reaching the suitable temperature. The first assay was made by heating 
the Au-SPE up to 90ºC, the same temperature that ensured previously that the anti-miRNA-
155 was linear and free to hybridize. The 90 ºC is indeed the typical denaturation temperature 
used in PCR (Polymerase chain reaction) assays, for which no irreversible denaturing or 
decoupling of oligonucleotide base pairs would be expected (Champaign, 2013).  
 
Figure 11: Regeneration of the biosensor (in green), at 90ºC (A, B, C) and 60 ºC (D, E, F), controlled by CV 
(A, D), EIS (B, E) and SWV (C, D), tested in 5.0×10-3 M [Fe(CN)6]3- and 5.0×10-3 M [Fe(CN)6]4- redox probe.  
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
0.20
-0.50 -0.30 -0.10 0.10 0.30 0.50
I
(m
A
)
Potential  
(V)
Au-SPE cleaned Anti-miRNA-155/Au-SPE cleaned Reused Au-SPE/Anti-miRNA-155/Au-SPE cleaned
A
0
100
200
300
400
0 200 400 600 800 1000
-Z
''
 (
Ω
)
Z' (Ω)
0.00
0.05
0.10
0.15
0.20
0.25
0.30
-0.2 0.3 0.8
I 
(m
A
)
Potential  (V)
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
0.20
-0.5 -0.3 -0.1 0.1 0.3 0.5
I
(m
A
)
Potential  
(V)
D D
0
100
200
300
400
0 200 400 600 800 1000
-Z
''
 (
Ω
)
Z' (Ω)
B
C
E
0.00
0.05
0.10
0.15
0.20
0.25
0.30
-0.2 0.3 0.8
I 
(m
A
)
Potential  (V)
F
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 60   
After 90ºC for 5 minutes, only little alterations were detected compared to the original signal 
of the biosensor before its hybridization: little shift in CV peaks; (Figure 11A); little decrease 
of the EIS resistance (Figure 11B); and a little increase of the peak current in SWV. Still, 
the small changes observed in the reused Au-SPE/anti-miRNA155 biosensor seemed to be 
related to the silver reference electrode modification/oxidation, promoted by such a high 
temperature (Figure 11C). This was visually perceptible. 
Thus, further assays were tested at lower temperature, in conjunction with a chemical buffer. 
For this, the hybridized biosensor was incubated in a saline-sodium citrate buffer (SSC) 
diluted 10× at 60ºC. After this, the signal of the regenerated surface matched exactly that of 
the original biosensor, in all electrochemical techniques (Figure 11, D, E and F).  
After recovering the original signal, the reused biosensor was calibrated again to evaluate its 
behaviour under a second calibration, and further on in a third calibration. This was made to 
test the ability of the complementary oligonucleotides remaining on the surface to hybridize 
with its target miRNA (because staying there would not grant its ability to hybridize). The 
calibration assays were made by EIS and SWV measurements again, and showed very 
similar analytical features to the original biosensor, calibrated by its first time.  
In EIS assays, the linear range was observed between 1.0 fM and 100 pM, plotting logarithm 
Rct against logarithm miRNA-155 concentration (Figure 12A). The slope was 0.0793 
logΩ/decade in the second calibration and changed to 0.0786 logΩ/decade in the third 
calibration, while the intercept was 4.1554 logΩ in the second calibration and changed to 
4.1364 logΩ in the third calibration. The standard deviation of the slope and intercept of all 
three calibrations performed in the same device was 5.2 and 0.3 %, meaning that the 
biosensor is able to generate reproducible calibrations after regeneration. Indeed, it is 
possible that the regeneration process has a little (but not relevant) impact on the biosensor 
response, as the standard deviation between second and third calibrations is much smaller 
(equal to 0.6 and 0.3 %, respectively). 
In SWV assays the calibration was also recovered in terms of concentration range, but the 
variability within the three calibrations was higher. The slope of the second calibration was 
-26.387 A/decade and changed to -31.929 A/decade in the following calibration, while 
the intercept was 201.5 A and changed to 257.6 A. The standard deviation of the slope 
and intercept of the three calibrations (first and two regenerated) was 9.5 and 16.0 %, which 
was clearly high, when compared with the EIS assays.  
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Overall, the biosensor may be regenerated after contacting with miRNA concentrations up 
to 100 nM, provided that the suitable approach is taken. In addition, EIS studies seem more 
reliable, if the Au-SPE is to be reused after its first calibration. This is particularly suitable 
for making the complete analytical procedure with a single chip (which may include 
calibration and sample analysis, all in a single device). 
 
Figure 12: Consecutive calibrations in the same chip, first and after regeneration, (A) in EIS and (B) in SWV assays, 
performed in 5.0×10-3 M [Fe(CN)6 ]3- and 5.0×10-3 M [Fe(CN)6]4-, in buffer (TRIS and EDTA with NaCl), pH 
7.4, in the same concentration range of miRNA-155 as before. 
 
III.3.4.7. Selectivity 
The selectivity study was conducted by evaluating the effect of chemical compounds present 
in biological fluids. A competitive assay was selected for this purpose. This was done by 
testing a solution of 10 pM miRNA-155 as single analyte and also in conjunction with other 
common biomolecules in serum, keeping the same concentration of miRNA-155. The 
incubation time was set to 30 minutes, the same period of time used in the calibration. 
The interfering compounds studied were CA-15-3 (protein biomarker that in breast cancer 
condition co-exists with miRNA-155 in serum) and BSA (highly concentrated protein in 
serum of normal/diseased person). These species were tested within their physiological 
levels. The % average deviation produced by each interfering species in pure miRNA-155 
solutions was 3.8 % when CA-15.3 was present and 5.17 % when BSA was added (Figure 
13). These assays were performed in triplicate using the same Au-SPE, accounting its 
reliability after regeneration in EIS measurements.  
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The extract of cell lines from melanoma was also tested herein. Melanoma is another 
condition of cancer where miRNA-155 is not expected to exist, at least in significant levels. 
The obtained signal was almost coincident to the blank, therefore indicating that no 
significant interference would be expected by applying this biosensor to real conditions. 
Overall, no significant interferences were observed in these tests, neither with single analytes 
nor with complex real cell extracts. 
 
Figure 13: Selectivity behaviour of the biosensor for miRNA-155 (10 pM) against CA-15.3 (30 U/mL) and 
BSA (0.30 µg/mL), after 30 minutes incubation and for the same redox probe tested before.  
 
III.3.4.8.  miRNA-155 assay in human serum samples 
The application of the biosensor to real samples was made after calibrating in standard 
solutions prepared in blank serum, instead of the buffer used until now. The analytical 
features of the resulting calibration curves in EIS and SWV were also evaluated at this stage.  
As before, EIS calibration curves plotted logarithm Rct (in EIS) against logarithm miRNA-
155 concentration. In general, the calibrations showed good analytical features in terms of 
lower concentration of linear range, LOD and slope (10aM, 5.7aM, 0.082 logΩ/decade) 
respectively (Figure 14B). Compared to the calibrations made with standard solutions 
prepared in buffer, this novel condition of preparing standards in serum had no significant 
impact in the slope (within the previous standard deviation), but unexpectedly had a 
favourable impact upon the concentration range enabling a response. The biosensor provided 
linear responses down to 10 aM with lower LODs than before. The calibrations in SWV 
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showed a similar behaviour (Figure 14C), with a decrease in the lower limit of linear range 
and LOD and a slope increase (1 aM, 0.18 aM, -36µA/decade, respectively). 
 
 
Figure 14: EIS(A) and SWV(C) measurements, and the corresponding calibration curves (B e D), in 5.0×10-3 
M [Fe(CN)6]3- and 5.0×10-3 M [Fe(CN)6]4-, in standard solutions prepared in a background of blank human 
serum, pH 7.4, with different concentration of miRNA-155. 
 
For sample analysis, real human serum serving as blank was spiked with miRNA-155 in two 
different concentrations: 100 fM and 100 pM. This was performed in triplicate and only by 
following EIS data. The calibration data used in the analysis to calculate the concentrations 
in the spiked serum was the one provided by the same biosensor before regeneration. 
Comparing added and found amounts, the relative errors obtained were 6.9 and 7.2%, 
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respectively. Overall, the results were found accurate in close-to-real conditions, as the 
device was tested in a background of control human serum of healthy individual. 
 
III.3.5. Conclusions 
This work described the development of a highly specific and very sensitive biosensor for 
the rapid detection of a cancer biomarker, miRNA155 present in serum. The biosensor 
assembly was very simple and effective, being temperature a critical step. Form the 
analytical perspective, the biosensor was able to detect very low concentrations of miRNA-
155, down to 1-10 aM in a serum background, and could be reused for consecutive readings 
of new solutions, most especially in EIS. In addition, the biosensor showed excellent 
selectivity towards other proteins in biological fluids and cell extracts from a side-cancer 
condition.  
This simple and sensitive strategy is considered a promising approach for the simultaneous 
quantitative analysis of multiple miRNA-155 in physiological fluids, in biomedical research 
and POC diagnosis. In addition, this device opens new horizons into real time monitoring of 
miRNA cancer biomarker in clinical context, also taking advantage of its ability de-hybridize 
and allowing reusing easily an on-line sensor.  
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IV. CHAPTER  
IV.1. Conclusion  
The miRNA can be new potential biomarkers is essential, in a way that combining various 
methodologies will allow having a more preventing way to confirm breast cancer and thus, 
apply a better treatment to the patient. 
So the biosensors are a great alternative method for detect the miRNA. In this case this 
biosensor is simply and rapidly method and shows a good analytical performance in 
synthetic serum with linear range, excellent specificity and reproducibility in all tests that 
used. 
 
The future work may include testing real samples, and use the mismatch method as another 
technique to confirm that the sensor is sensitive and specific. Also, a good alternative may 
be to continue the work with cell lines and compare the biosensor response with another 
method, such as PCR.  
  
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 70   
 
  71   
V. REFERENCES   
Azimzadeh, M., Rahaie, M., Nasirizadeh, N., Ashtari, K., & Naderi-Manesh, H. (2015). An electrochemical 
nanobiosensor for plasma miRNA-155, based on graphene oxide and gold nanorod, for early detection 
of breast cancer. Biosensors & Bioelectronics, 77, 99–106. http://doi.org/10.1016/j.bios.2015.09.020 
Bohunicky, B., & Mousa, S. a. (2011). Biosensors: The new wave in cancer diagnosis. Nanotechnology, 
Science and Applications, 4(1), 1–10. http://doi.org/10.2147/NSA.S13465 
Bourigua, S., Maaref, a., Bessueille, F., & Renault, N. J. (2013). A New Design of Electrochemical and Optical 
Biosensors Based on Biocatalytic Growth of Au Nanoparticles - Example of Glucose Detection. 
Electroanalysis, 25(3), 644–651. http://doi.org/10.1002/elan.201200243 
Campuzano, S., Pedrero, M., & Pingarrón, J. M. (2014). Electrochemical genosensors for the detection of 
cancer-related miRNAs. Analytical and Bioanalytical Chemistry, 406(1), 27–33. 
http://doi.org/10.1007/s00216-013-7459-z 
Catuogno, S., Esposito, C. L., Quintavalle, C., Cerchia, L., Condorelli, G., & de Franciscis, V. (2011). Recent 
advance in biosensors for microRNAs detection in cancer. Cancers, 3(2), 1877–1898. 
http://doi.org/10.3390/cancers3021877 
Champaign, U. (2013). Polymerase Chain Reaction. Brenner’s Encyclopedia of Genetics, Second Edition, 5(3), 
392–395. http://doi.org/10.1016/B978-0-12-374984-0.01186-4 
Choi, Y.-E., Kwak, J.-W., & Park, J. W. (2010). Nanotechnology for Early Cancer Detection. Sensors, 10(1), 
428–455. http://doi.org/10.3390/s100100428 
Chung, L., Moore, K., Phillips, L., Boyle, F. M., Marsh, D. J., & Baxter, R. C. (2014). Novel serum protein 
biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer 
Research : BCR, 16(3), R63. http://doi.org/10.1186/bcr3676 
Dong, H., Zhang, J., Ju, H., Lu, H., Wang, S., Jin, S., … Zhang, X. (2012). Highly sensitive multiple microRNA 
detection based on fluorescence quenching of graphene oxide and isothermal strand-displacement 
polymerase reaction. Analytical Chemistry, 84(10), 4587–4593. http://doi.org/10.1021/ac300721u 
Fan, Y., Chen, X. T., Tung, C. H., Kong, J. M., & Gao, Z. Q. (2007). Electrical detection of nucleic acids using 
target-guided formation of conducting polymer nanowires in nanogaps. TRANSDUCERS and 
EUROSENSORS ’07 - 4th International Conference on Solid-State Sensors, Actuators and 
Microsystems, (15), 1887–1890. http://doi.org/10.1109/SENSOR.2007.4300526 
Fu, S. W., Chen, L., & Man, Y.-G. (2011). miRNA Biomarkers in Breast Cancer Detection and Management. 
Journal of Cancer, 2, 116–122. http://doi.org/10.7150/jca.2.116 
Gao, Z., & Yang, Z. (2006). Detection of microRNAs using electrocatalytic nanoparticle tags. Analytical 
Chemistry, 78(5), 1470–1477. http://doi.org/10.1021/ac051726m 
Goode, J. A., Rushworth, J. V. H., & Millner, P. A. (2014). Biosensor Regeneration : A Review of Common 
Techniques and Outcomes. 
Grieshaber, D., MacKenzie, R., Vörös, J., & Reimhult, E. (2008). Electrochemical Biosensors - Sensor 
Principles and Architectures. Sensors, 8(3), 1400–1458. http://doi.org/10.3390/s8031400 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 72   
Hamidi-Asl, E., Hasheminejad, E., & Mascini, M. (2013). A review on the electrochemical biosensors for 
determination of microRNAs. Talanta, 115, 74–83. http://doi.org/10.1016/j.talanta.2013.03.061 
Harvey, D. (2000). Modern Analytic Chemistry, 797. 
He, Y., Lin, J., Kong, D., Huang, M., Xu, C., Kim, T.-K., … Wang, K. (2015). Current State of Circulating 
MicroRNAs as Cancer Biomarkers. Clinical Chemistry, 61(9), 1138–1155. 
http://doi.org/10.1373/clinchem.2015.241190 
Hu, T., Zhang, L., Wen, W., Zhang, X., & Wang, S. (2015). Enzyme catalytic amplification of miRNA-155 
detection with graphene quantum dot-based electrochemical biosensor. Biosensors and Bioelectronics, 
77, 451–456. http://doi.org/10.1016/j.bios.2015.09.068 
Jamali, A. A., Pourhassan-Moghaddam, M., Dolatabadi, J. E. N., & Omidi, Y. (2014). Nanomaterials on the 
road to microRNA detection with optical and electrochemical nanobiosensors. TrAC - Trends in 
Analytical Chemistry, 55, 24–42. http://doi.org/10.1016/j.trac.2013.10.008 
Johnson, B. N., & Mutharasan, R. (2014). Biosensor-based microRNA detection: techniques, design, 
performance, and challenges. The Analyst, 139(7), 1576. http://doi.org/10.1039/c3an01677c 
Koyun, A., Ahlatcıoğlu, E., & İpek, Y. K. (2012). Biosensors and Their Principles. A Roadmap of Biomedical 
Engineers and Milestones, 117–142. http://doi.org/10.5772/48824 
Labib, M., & Berezovski, M. V. (2015). Electrochemical sensing of microRNAs: Avenues and paradigms. 
Biosensors and Bioelectronics, 68, 83–94. http://doi.org/10.1016/j.bios.2014.12.026 
Labib, M., Khan, N., & Berezovski, M. V. (2015). Protein Electrocatalysis for Direct Sensing of Circulating 
MicroRNAs. Analytical Chemistry, 87(2), 1395–1403. http://doi.org/10.1021/ac504331c 
Lee, a. V., Oesterreich, S., & Davidson, N. E. (2015). MCF-7 Cells--Changing the Course of Breast Cancer 
Research and Care for 45 Years. JNCI Journal of the National Cancer Institute, 107(7), djv073–djv073. 
http://doi.org/10.1093/jnci/djv073 
Li, F., Peng, J., Wang, J., Tang, H., Tan, L., Xie, Q., & Yao, S. (2014). Carbon nanotube-based label-free 
electrochemical biosensor for sensitive detection of miRNA-24. Biosensors and Bioelectronics, 54, 158–
164. http://doi.org/10.1016/j.bios.2013.10.061 
Liu, J., Huang, W., Yang, H., & Luo, Y. (2015). Expression and function of miR- 155 in breast cancer. 
Biotechnology & Biotechnological Equipment, 29(5), 840–843. 
http://doi.org/10.1080/13102818.2015.1043946 
Liu, S., Su, W., Li, Z., & Ding, X. (2015). Electrochemical detection of lung cancer specific microRNAs using 
3D DNA origami nanostructures. Biosensors and Bioelectronics, 71, 57–61. 
http://doi.org/10.1016/j.bios.2015.04.006 
Liu, X., Duckworth, P. a., & Wong, D. K. Y. (2010). Square wave voltammetry versus electrochemical 
impedance spectroscopy as a rapid detection technique at electrochemical immunosensors. Biosensors 
and Bioelectronics, 25(6), 1467–1473. http://doi.org/10.1016/j.bios.2009.10.047 
Marli, C., & Paiva, C. (2011). Biosensors for Health Applications. Biomedical Engineering, 71–86. 
Mattiske, S., Suetani, R. J., Neilsen, P. M., & Callen, D. F. (2012). The oncogenic role of miR-155 in breast 
cancer. Cancer Epidemiology Biomarkers and Prevention, 21(8), 1236–1243. 
http://doi.org/10.1158/1055-9965.EPI-12-0173 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 73   
Miao, P., Wang, B., Yu, Z., Zhao, J., & Tang, Y. (2015). Ultrasensitive electrochemical detection of microRNA 
with star trigon structure and endonuclease mediated signal amplification. Biosensors and 
Bioelectronics, 63, 365–370. http://doi.org/10.1016/j.bios.2014.07.075 
Mirabelli, P., & Incoronato, M. (2013). Usefulness of Traditional Serum Biomarkers for Management of Breast 
Cancer Patients, 2013. 
Panagopoulou, M. a., Stergiou, D. V., Roussis, I. G., & Prodromidis, M. I. (2010). Impedimetric biosensor for 
the assessment of the clotting activity of rennet. Analytical Chemistry, 82(20), 8629–8636. 
http://doi.org/10.1021/ac1017925 
Peng, Y., Yi, G., & Gao, Z. (2010). A highly sensitive microRNA biosensor based on ruthenium oxide 
nanoparticle-initiated polymerization of aniline. Chemical Communications (Cambridge, England), 
46(48), 9131–3. http://doi.org/10.1039/c0cc01990a 
Perry, N., Broeders, M., de Wolf, C., Törnberg, S., Holland, R., & von Karsa, L. (2008). European guidelines 
for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. 
Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO, 19(4), 
614–622. http://doi.org/10.1093/annonc/mdm481 
Perumal, V., & Hashim, U. (2014). Advances in biosensors: Principle, architecture and applications. Journal 
of Applied Biomedicine, 12(1), 1–15. http://doi.org/10.1016/j.jab.2013.02.001 
Putzbach, W., & Ronkainen, N. J. (2013). Immobilization techniques in the fabrication of nanomaterial-based 
electrochemical biosensors: a review. Sensors (Basel, Switzerland), 13(4), 4811–4840. 
http://doi.org/10.3390/s130404811 
Riaz, M., van Jaarsveld, M. T., Hollestelle, A., Prager-van der Smissen, W. J., Heine, A. A., Boersma, A. W., 
… Martens, J. W. (2013). miRNA expression profiling of 51 human breast cancer cell lines reveals 
subtype and driver mutation-specific miRNAs. Breast Cancer Research : BCR, 15(2), R33. 
http://doi.org/10.1186/bcr3415 
RNA Nanotechnology. (2014). CRC Press. Retrieved from 
https://books.google.com/books?id=NB0yAwAAQBAJ&pgis=1 
Siegel, R., Desantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., … Fedewa, S. (2012). Cancer Treatment 
and Survivorship Statistics , 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241. 
http://doi.org/10.3322/caac.21149. 
Song, S., Xu, H., & Fan, C. (2006). Potential diagnostic applications of biosensors: Current and future 
directions. International Journal of Nanomedicine, 1(4), 433–440. 
http://doi.org/10.2147/nano.2006.1.4.433 
Su, L., Jia, W., Hou, C., & Lei, Y. (2011). Microbial biosensors: A review. Biosensors and Bioelectronics, 
26(5), 1788–1799. http://doi.org/10.1016/j.bios.2010.09.005 
Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., & Li, J. (2012). Serum MicroRNA-155 as a Potential 
Biomarker to Track Disease in Breast Cancer. PLoS ONE, 7(10), 1–8. 
http://doi.org/10.1371/journal.pone.0047003 
Suni, I. I. (2008). Impedance methods for electrochemical sensors using nanomaterials. TrAC - Trends in 
Analytical Chemistry, 27(7), 604–611. http://doi.org/10.1016/j.trac.2008.03.012 
Tavallaie, R., De Almeida, S. R. M., & Gooding, J. J. (2015). Toward biosensors for the detection of circulating 
microRNA as a cancer biomarker: an overview of the challenges and successes. Wiley Interdisciplinary 
Reviews: Nanomedicine and Nanobiotechnology, 7(4), 580–592. http://doi.org/10.1002/wnan.1324 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 74   
Tran, H. V., Piro, B., Reisberg, S., Anquetin, G., Duc, H. T., & Pham, M. C. (2014). An innovative strategy 
for direct electrochemical detection of microRNA biomarkers. Analytical and Bioanalytical Chemistry, 
406(4), 1241–1244. http://doi.org/10.1007/s00216-013-7292-4 
Tran, H. V., Piro, B., Reisberg, S., Tran, L. D., Duc, H. T., & Pham, M. C. (2013). Label-free and reagentless 
electrochemical detection of microRNAs using a conducting polymer nanostructured by carbon 
nanotubes: Application to prostate cancer biomarker miR-141. Biosensors and Bioelectronics, 
49(September), 164–169. http://doi.org/10.1016/j.bios.2013.05.007 
Tu, Y., Li, W., Wu, P., Zhang, H., & Cai, C. (2013). Fluorescence quenching of graphene oxide integrating 
with the site-specific cleavage of the endonuclease for sensitive and selective microRNA detection. 
Analytical Chemistry, 85(4), 2536–2542. http://doi.org/10.1021/ac303772m 
Volinia, S., Galasso, M., Sana, M. E., Wise, T. F., Palatini, J., Huebner, K., & Croce, C. M. (2012). Breast 
cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proceedings 
of the National Academy of Sciences, 109(8), 3024–3029. http://doi.org/10.1073/pnas.1200010109 
Wang, D., Hu, L., Zhou, H., Abdel-Halim, E. S., & Zhu, J. J. (2013). Molecular beacon structure mediated 
rolling circle amplification for ultrasensitive electrochemical detection of microRNA based on quantum 
dots tagging. Electrochemistry Communications, 33, 80–83. 
http://doi.org/10.1016/j.elecom.2013.04.030 
Wen, Y., Pei, H., Shen, Y., Xi, J., Lin, M., Lu, N., … Fan, C. (2012). DNA Nanostructure-based Interfacial 
engineering for PCR-free ultrasensitive electrochemical analysis of microRNA. Scientific Reports, 2, 
867. http://doi.org/10.1038/srep00867 
Wu, S., Chen, H., Zuo, Z., Wang, M., Luo, R., & Xu, H. (2015). A Simple Electrochemical Biosensor for 
Rapid Detection of MicroRNA Based on Base Stacking Technology and Enzyme Amplification, 10, 
3848–3858. 
Wu, X., Chai, Y., Yuan, R., Su, H., & Han, J. (2013). A novel label-free electrochemical microRNA biosensor 
using Pd nanoparticles as enhancer and linker. The Analyst, 138(4), 1060–6. 
http://doi.org/10.1039/c2an36506e 
Wu, X., Chai, Y., Zhang, P., Yuan, R. (2015). An electrochemical biosensor for sensitive detection of 
microRNA-155: combining target recycling with cascade catalysis for signal amplification, ACS Appl 
Materials and Interfaces, 7(1),713-20. doi: 10.1021/am507059n. 
Yahalom, G., Weiss, D., Novikov, I., Bevers, T. B., Radvanyi, L. G., Liu, M., … Rosenberg, M. M. (2013). 
An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast 
Cancer Diagnosis. Biomarkers in Cancer, 5, 71–80. http://doi.org/10.4137/BIC.S13236 
Yan, Y., Zhao, D., Yuan, T., Hu, J., Zhang, D., Cheng, W., … Ding, S. (2013). A simple and highly sensitive 
electrochemical biosensor for microRNA detection using target-assisted isothermal exponential 
amplification reaction. Electroanalysis, 25(10), 2354–2359. http://doi.org/10.1002/elan.201300328 
Yin, H., Zhou, Y., Chen, C., Zhu, L., & Ai, S. (2012). An electrochemical signal “off–on” sensing platform for 
microRNA detection. The Analyst, 137(6), 1389. http://doi.org/10.1039/c2an16098f 
Zeng, H., Fang, C., Nam, S., Cai, Q., & Long, X. (2014). The Clinicopathological Significance of MicroRNA-
155 in Breast Cancer : A Meta-Analysis, 2014. 
Zhang, C.-M., Zhao, J., & Deng, H.-Y. (2013). MiR-155 promotes proliferation of human breast cancer MCF-
7 cells through targeting tumor protein 53-induced nuclear protein 1. Journal of Biomedical Science, 
20(1), 79. http://doi.org/10.1186/1423-0127-20-79 
Development of an electrochemical biosensor for the detection of the miRNA-155 in Breast Cancer 
 75   
Zhu, W., Su, X., Gao, X., Dai, Z., & Zou, X. (2014). A label-free and PCR-free electrochemical assay for 
multiplexed microRNA profiles by ligase chain reaction coupling with quantum dots barcodes. 
Biosensors & Bioelectronics, 53, 414–9. http://doi.org/10.1016/j.bios.2013.10.023 
 
 
